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Abstract: The first Food and Drug Administration-(FDA)-approved drugs were small, chemically-
manufactured and highly active molecules with possible off-target effects, followed by protein-based
medicines such as antibodies. Conventional antibodies bind a specific protein and are becoming
increasingly important in the therapeutic landscape. A very prominent class of biologicals are
the anti-tumor necrosis factor (TNF) drugs that are applied in several inflammatory diseases that
are characterized by dysregulated TNF levels. Marketing of TNF inhibitors revolutionized the
treatment of diseases such as Crohn’s disease. However, these inhibitors also have undesired
effects, some of them directly associated with the inherent nature of this drug class, whereas others
are linked with their mechanism of action, being pan-TNF inhibition. The effects of TNF can
diverge at the level of TNF format or receptor, and we discuss the consequences of this in sepsis,
autoimmunity and neurodegeneration. Recently, researchers tried to design drugs with reduced
side effects. These include molecules with more specificity targeting one specific TNF format or
receptor, or that neutralize TNF in specific cells. Alternatively, TNF-directed biologicals without the
typical antibody structure are manufactured. Here, we review the complications related to the use of
conventional TNF inhibitors, together with the anti-TNF alternatives and the benefits of selective
approaches in different diseases.
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1. Introduction
Since the discovery and identification of tumor necrosis factor (TNF) in the mid 1980s [1],
novel techniques allowed the isolation and cloning of the TNF gene for further characterization
and TNF became the subject in a lot of studies. Originally, TNF was identified as a factor that necrotizes
certain tumors [2,3] and recombinant TNF was useful to discover the biological functions of TNF.
As a tumor-necrotizing agent, TNF’s toxicity in animal models was apparently acceptable, thus TNF
was quickly launched into clinical trials. Eighteen monotherapy phase I and 10 phase II clinical
trials were performed using recombinant human TNF (hTNF) therapy as anti-cancer agent, but none
of them was successful as systemic TNF treatment was found to cause dose-dependent toxicities
such as fever, hypotension and tachycardia [4–6]. Based on these and other studies, it became clear
that TNF is a pleiotropic cytokine with major roles in physiology and pathology, amongst others by
causing necrotic and apoptotic cell death, cellular regulation, differentiation, inflammation and the
regulation of immune cells, and tumorigenesis [7]. The executive functions of TNF exceed multiple
disciplines as TNF is important in homeostatic processes as well as in pathological situations ranging
from inflammation, neurodegenerative diseases and infections.
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Today, 19 members of the TNF superfamily have been identified, based on sequence similarity
with TNF. In addition, 29 interacting receptors and several molecules interacting with the cytoplasmic
domain of these receptors are recognized [1,7]. All members of the TNF receptor (TNFR) family
contain one to six cysteine-rich repeats in their extracellular domains, typically each with three cysteine
bridges within their structure [8]. The receptors can be classified in two subgroups: the death domain
(DD)-containing receptors and the tumor necrosis factor receptor-associated factor (TRAF)-interacting
receptors [9].
2. Biology
TNF is expressed as a 26 kDa transmembrane protein (tmTNF) which can be shed by the
metalloproteinase TNF-α-converting enzyme (TACE) or disintegrin and metalloproteinase 17 ADAM17
to release the homotrimeric soluble TNF form (sTNF, monomeric 17 kDa) [10]. TNF is produced by a
variety of cell types, such as monocytes and macrophages, T cells, natural killer (NK) cells, neutrophils,
and microglia as well as by non-immune cells such as neuronal cells or keratinocytes. Both tmTNF as
well as sTNF are biologically active, and the balance between these two forms is influenced by the cell
type and its activation status, TACE activity and the expression of the endogenous TACE inhibitor,
tissue inhibitor of metalloproteinase (TIMP)-3 [11,12]. TNF binds two homotrimeric transmembrane
receptors: the 55 kDa TNF receptor 1 (TNFR1 or CD120a), encoded by the TNFRSF1A gene and the
75 kDa TNF receptor 2 (TNFR2 or CD120b), encoded by TNFRSF1B [9]. Interestingly, instead of
only being a ligand, tmTNF can also act as a receptor because tmTNF-bearing cells show biological
activity via reverse signaling when activated by mainly TNFR2. However, the biological functions
elicited by this “outside-to-inside signaling” have not been completely elucidated [13]. TNFR1 is
constitutively and ubiquitously expressed on a broad variety of cells, whereas expression of TNFR2
is inducible and tightly regulated. TNFR2 expression is more restricted and can be typically found
on endothelial, immune (including microglia) and neuronal cells [9]. Recently, TNFR2 has also been
found to be expressed on tumor cells and has been suggested to function as a tumor oncogene [14,15].
The extracellular domains of the two receptors are conserved and consist of a pre-ligand assembly
domain (PLAD) and a ligand-binding domain, which is composed of four cysteine-rich domains and a
TACE substrate domain. The PLAD stabilizes the receptors in absence of ligand as homophilic dimers.
PLAD-mediated receptor preassembly is necessary for TNF/TNFR signaling and deletion of PLAD
completely abrogates ligand binding and signaling [16]. In contrast to their extracellular domains,
their intracellular domains are unrelated, explaining the initiation of different signaling cascades [17].
TNFR1 is a DD-containing receptor allowing protein–protein interactions, while TNFR2 does not have
such a DD [18,19]. Successful signaling via TNF requires receptor preassembly as trimers prior to
ligand binding. Preassembly occurs through the intracellular cytoplasmic tail of the receptors. The DD
can recruit two adaptor DD-containing proteins, namely TNFR1-associated death domain (TRADD) or
Fas-associated death domain (FADD), whereupon the apoptotic pathway is activated and the caspase
cascade is engaged [20]. Importantly, in addition to other ligands such as Fas and TRIAL, TNF via
TNFR1 can activate a caspase-independent pro-inflammatory cell death, called necroptosis [21–23].
This is a relatively novel programmed necrosis-like inflammatory process.
Upon TNFR2 activation, this receptor recruits TRAF2 and other TRAF2-associated proteins,
as well as interacts with other signaling proteins that act independently of TRAF2. Whereas TNFR1
is linked with pro-inflammatory and apoptotic effects, TNFR2 has been associated with a variety of
immune regulatory and anti-inflammatory functions [20]. Importantly, a complex interplay between
TNFR1 and TNFR2 has been described, and additive, synergistic as well as antagonistic effects have
been demonstrated [9].
TNFR1 is activated by either sTNF as well as tmTNF, while TNFR2 can only be activated by tmTNF.
Hence, the role of TNFR2 is thought to be underestimated [24]. The membrane-bound forms of both
receptors are also a substrate for proteolytical cleavage by TACE, yielding soluble receptor fragments
e.g., soluble TNF receptor (sTNFR) [25]. This process is an important self-regulatory mechanism to
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prevent exaggerated damage and may contribute to the regulation of cellular TNF responsiveness [25].
Increased ectodomain shedding has three consequences: (1) On the one hand, the shed receptors can
neutralize the bioactivity of circulating TNF by sequestering it. Hence, sTNFR will act as an intrinsic
TNF inhibitor. (2) On the other hand, the process will decrease the number of signaling-competent
receptors on the cell surface and cause transient TNF desensitization [26]. Accordingly, mice expressing
non-sheddable TNFR1 spontaneously develop liver pathology and autoimmunity, pointing towards
the pivotal role of TNFR1 shedding to regulate TNF activity in vivo [27]. The importance of this system
is also highlighted in the disease condition of TRAPS (TNF receptor-associated periodic syndrome),
an autosomal dominantly inherited disease characterized by unprovoked, often prolonged, attacks of
fever and inflammation in multiple organs caused by a mutation in TNFSFR1A [28]. (3) Alternatively,
sTNFR1 can form a stable complex with sTNF which can act as a sink in which the circulating TNF
levels will be preserved.
3. TNF in Health and Disease
TNF is a pleiotropic cytokine and a master regulator of the immune system, and most cells show
at least some TNF responsiveness. Studies revealed two opposite functions of TNF in host defense. At
low levels, TNF has beneficial homeostatic functions, such as for host defense mechanisms against
for example intracellular pathogens, particularly mycobacteria such as Mycobacterium tuberculosis [29].
However, at high concentrations, TNF can be deleterious and promotes inflammation and organ
injury. In disease states, TNF is predominantly secreted by macrophages and monocytes both
systemically and locally in the affected tissues, but also many other cells can produce TNF under
certain circumstances [30].
3.1. Homeostatic Functions of TNF in Immunity
The use of transgenic mice greatly enhanced our knowledge about the different functions of
TNF. TNF deficient mice revealed that TNF has prominent homeostatic functions in addition to its
pro-inflammatory roles, and is vital for an optimal functioning of our immune system needed for host
defense. Indeed, it has been shown that TNF is required to develop splenic B cell follicles, for the
organization of the secondary lymphoid tissue architecture, and for germinal center (GC) and follicular
dendritic cell (FDC) formation. Additionally, TNF is indispensable to fight pathogens and prevent
further pathogen spreading by the formation and maintenance of granulomas, which are organized
accumulations of infected macrophages and lymphocytes [31,32]. Likewise, TNF is highly needed
for the resolution of inflammation and to promote tissue repair illustrated by its need for neuronal
remyelination, cardiac remodeling and cartilage regeneration. The homeostatic potential of TNF has
been proposed to be mainly mediated by TNF/TNFR2 signaling [33–35].
As mentioned earlier, the indispensable role of TNF for host defense against (intracellular) bacteria,
viruses and fungi is well documented. Indeed, alone, together, or in synergy with interferons (IFNs),
TNF is the most potent mediator in this process and it needs both TNF receptors for an efficient
defense. Via the induction of chemokines and adhesion molecules [36], TNF is indirectly involved in
the recruitment of inflammatory innate immune cells such as neutrophils, monocytes, NK cells and
the so-called antigen presenting cells (APCs): immature tissue resident macrophages and dendritic
cells (DCs). TNF enhances the pathogen-directed cytotoxicity of the innate immune cells and acts
as a stimulatory agent for phagocytes [37]. In addition, TNF-induced NF-κB is required to convert
immature tissue resident DCs into functionally mature effector cells. The latter will then stimulate
naive T cells in nearby draining lymph nodes to initiate antigen-specific T and B cell responses [38].
For example, TNF is essential for a normal host response to Mycobacterium bovis and, more specifically,
TNF derived from hematopoietic cells rather than from stromal origin [39]. To control M. tuberculosis,
it has been shown that myeloid and T cells are the primary sources of TNF: myeloid cell-derived TNF
is implicated in early immune responses, whereas T cell-derived TNF is essential to sustain protection
during chronic infections [40].
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Most of the pro-inflammatory functions are mediated by TNFR1, as mice deficient for TNFR1 are
highly susceptible to Listeria monocytogenis and M. tuberculosis infection, and TNFR1 is also required
for the anti-viral response via induction of apoptotic cell death [38,41]. Moreover, loss-of-function
due to TNF knockout is highly mimicked by TNFR1 deficiency [42]. The role of TNF/TNFR1
signaling in M. tuberculosis infection relates to its contribution in granuloma formation that is
needed to control the infection. Additionally, it may relate to macrophage activation to produce
reactive nitrogen species to destroy intracellular bacteria [43]. Interestingly, mice that express a
non-cleavable variant of TNF were partially protected against M. tuberculosis, L. monocytogenes and
M. bovis, indicating that tmTNF signaling, which predominantly occurs via TNFR2, is needed for
this protection [44]. In addition, mice that express non-cleavable TNFR1 were more resistant to
L. monocytogenes infections, suggesting that impaired TNFR1 shedding enhances the antibacterial host
defense [27]. Additionally, a recent study indicates that TNFR1 on myeloid and not on T cells is crucial
to control M. tuberculosis infection [45].
3.2. Systemic Inflammation
3.2.1. TNF: The Master Regulator of Inflammation
Sepsis is a very complex syndrome that is caused by a dysregulated host response to infection.
It is characterized by sustained excessive inflammation and immune suppression, and many studies
have shown that TNF is the master mediator of the inflammatory response seen in sepsis and shock,
the life-threatening condition caused by circulatory and/or metabolic abnormalities. Indeed, TNF is
released from macrophages into the systemic circulation as early as 30 min after an inciting event such
as an intraperitoneal (ip) lipopolysaccharide (LPS) injection, with peak concentrations observed after
60–90 min [46]. This primes the activation of other inflammatory mediators such as interleukin (IL-)1.
Depending on where TNF is produced and on which cell it acts, TNF not only potently promotes the
release of the secondary mediator IL-6, but also drives its own production. The excessive production of
pro-inflammatory mediators is followed by a wave of counteracting and anti-inflammatory mediators
such as soluble TNFR that sequesters its bioactive ligand [47] (Figure 1). During bacterial infections,
these cytokines are the main drivers and are the central mediators of the induced shock after either
Gram-positive or Gram-negative bacteremia [38,48]. Thus, dysregulation of the TNF production due to
an overreaction of the host may have unforeseeable consequences. In animals, exogenous TNF
administration leads to a syndrome that is indistinguishable from septic shock and infusion of
TNF into humans results in systemic inflammatory response syndrome (SIRS) [49]. Consequently,
sustained elevated endogenous TNF levels can lead to a SIRS, which may evolve to death due to
multiple organ failure (MOF). Several studies demonstrate that TNF serum levels in sepsis patients
are elevated and associated with mortality [50,51] and they are used as effective markers in the
diagnosis of neonatal sepsis [52]. These observations led to the rationale to therapeutically neutralize
circulating TNF in septic patients. However, numerous clinical trials failed to demonstrate clear
statistical benefits [53–59]. As sepsis involves the presence of a pathogen, the inability to control the
infection when TNF signaling is abrogated might account for the failure seen in these clinical trials.
Indeed, in sterile sepsis models (i.e., LPS-induced shock), anti-TNF treated mice show some degree
of protection but this is not recapitulated in real infection models such as cecal ligation and puncture
(CLP) [60,61]. However, a meta-analysis suggests that immunotherapy with monoclonal antibodies
(mAbs) against TNF does reduce the overall mortality in severe septic patients when the drugs is
administered before shock. Furthermore, it may improve survival in patients with shock or with high
IL6 levels, and thus requires patient stratification [62].
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Figure 1. Cytokine kinetics in sepsis. Tumor necrosis factor (TNF) and interleukin (IL-)1 are the first 
cytokines to be released in sepsis and promote the secretion of IL-6. Together, these cytokines are the 
orchestrators during the pro-inflammatory phase in sepsis. After some time, compensation 
mechanisms arise to dampen the pro-inflammatory response such as IL-10, IL-1 receptor antagonist 
(IL-1Ra) and soluble TNF receptor (sTNFR). Figure adapted from [63]. 
3.2.2. Differential Roles for TNFR1 and TNFR2 in Sepsis 
In sepsis, a differential role for TNFR1 and TNFR2 has been uncovered by using transgenic mice 
in several experimental models, although their exact contributions remain debatable. Mice deficient 
for TNFR1 were protected against death when they were subjected to endotoxemia, i.e., the injection 
of a lethal dose of LPS [64,65], whereas TNFR2 knockout (KO) mice were as sensitive as wild type 
(WT) mice [66]. At the level of the gut, Williams et al. reported that TNFR1 is essential for LPS-
induced gut injury by mediating apoptosis of intestinal epithelial cells (IECs) [67], and also in the 
TNF-induced lethal shock model, the complete survival benefit in TNFR1 KO mice was attributed to 
the avoidance of TNF-induced gut permeability [41,68,69]. Additionally, the blood–cerebrospinal 
fluid (CSF) barrier permeability was also less comprised in endotoxic TNFR1 KO mice [70]. This is an 
important observation, as preservation of the integrity of the brain barriers might overcome the 
occurrence of sepsis-associated encephalopathy (SAE) [71]. This devastating complication of sepsis 
is associated with early death in sepsis patients [72]. It has been suggested that TNFR1 is a critical 
mediator in the onset of SAE because of its stimulating effects on aquaporin-4 and concomitant 
increase in water content in the brain [73]. Interestingly, TNFR1−/− mice also experienced less sepsis-
induced memory deficits [74]. However, despite of these interesting observations, TNFR1 KO mice 
were not protected against very high LPS doses [42,66], which was also confirmed in our lab [70]. The 
previous models are sterile models, and observations in CLP, which is considered as the golden 
standard for human polymicrobial sepsis [75], or in colon ascendens stent peritonitis (CASP) left the 
scientific community with contradictory results regarding the different roles of TNFR1 and TNFR2 
in real sepsis models. Some groups, including ours, found that TNFR1 deficient mice were as 
sensitive as WT mice in CASP or CLP [70,76,77], whereas others reported that TNFR1 KO mice had 
prolonged survival in CLP and that TNFR2 KO mice were more sensitive than WT mice [78]. When 
polymicrobial sepsis was initiated by ip injection of cecal microflora, the levels of TNF were severely 
elevated and mice deficient for TNFR1 or both TNFRs survived the induced sepsis [61]. Collectively, 
these studies fail to provide a clear consensus about the exact contribution of each receptor. These 
data also suggest that lethality does not only depend on TNF, but also other inflammatory mediators 
contribute to the LPS-induced lethality for instance IL-1β or matrix metalloproteinases (MMPs) [79]. 
Indeed, former research of the lab reported an important interplay between TNFR1 signaling and 
MMP8 in sepsis [70]. We found a link between these two mediators in sepsis patients and mice 
Figure 1. Cytokine kinetics in sepsis. Tumor necrosis factor (TNF) and interleukin (IL-)1 are the first
cytokines to be released in sepsis and promote the secretion of IL-6. Together, these cytokines are the
orchestrators during the pro-inflammatory phase in sepsis. After some time, compensation mechanisms
arise to dampen the pro-inflammatory response such as IL-10, IL-1 receptor antagonist (IL-1Ra) and
soluble TNF receptor (sTNFR). Figure adapted from [63].
3.2.2. Differential Roles for TNFR1 and TNFR2 in Sepsis
In sepsis, a differential role for TNFR1 and TNFR2 has been uncovered by using transgenic mice
in several experimental models, although their exact contributions remain debatable. Mice deficient
for TNFR1 were protected against death when they were subjected to endotoxemia, i.e., the injection of
a lethal dose of LPS [64,65], whereas TNFR2 knockout (KO) mice were as sensitive as wild type (WT)
mice [66]. At the level of the gut, Williams et al. reported that TNFR1 is essential for LPS-induced gut
injury by mediating apoptosis of intestinal epithelial cells (IECs) [67], and also in the TNF-induced
lethal shock model, the complete survival benefit in TNFR1 KO mice was attributed to the avoidance
of TNF-induced gut permeability [41,68,69]. Additionally, the blood–cerebrospinal fluid (CSF) barrier
permeability was also less comprised in endotoxic TNFR1 KO mice [70]. This is an important
observation, as preservation of the integrity of the brain barriers might overcome the occurrence
of sepsis-associated encephalopathy (SAE) [71]. This devastating complication of sepsis is associated
with early death in sepsis patients [72]. It has been suggested that TNFR1 is a critical mediator in
the onset of SAE because of its stimulating effects on aquaporin-4 and concomitant increase in water
content in the brain [73]. Interestingly, TNFR1−/− mice also experienced less sepsis-induced memory
deficits [74]. However, despite of these interesting observations, TNFR1 KO mice were not protected
against very high LPS doses [42,66], which was also confirmed in our lab [70]. The previous models
are sterile models, and observations in CLP, which is considered as the golden standard for human
polymicrobial sepsis [75], or in colon ascendens stent peritonitis (CASP) left the scientific community
with contradictory results regarding the different roles of TNFR1 and TNFR2 in real sepsis models.
Some groups, including ours, found that TNFR1 deficient mice were as sensitive as WT mice in CASP or
CLP [70,76,77], whereas others reported that TNFR1 KO mice had prolonged survival in CLP and that
TNFR2 KO mice were more sensitive than WT mice [78]. When polymicrobial sepsis was initiated by
ip injection of cecal microflora, the levels of TNF were severely elevated and mice deficient for TNFR1
or both TNFRs survived the induced sepsis [61]. Collectively, these studies fail to provide a clear
consensus about the exact contribution of each receptor. These data also suggest that lethality does not
only depend on TNF, but also other inflammatory mediators contribute to the LPS-induced lethality for
instance IL-1β or matrix metalloproteinases (MMPs) [79]. Indeed, former research of the lab reported
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an important interplay between TNFR1 signaling and MMP8 in sepsis [70]. We found a link between
these two mediators in sepsis patients and mice deficient for the both genes were significantly more
protected against very lethal endotoxemia and CLP-induced peritonitis than WT or single KO mice.
Hence, our research group created a bivalent Camelid-derived heavy-chain only Ab, namely Nanobody
(Nb) 70-alb-14, that simultaneously antagonizes TNFR1 and MMP8. Proof-of-concept was provided as
treatment with this Nb reduced lethality against CLP [70].
3.3. Autoimmunity
3.3.1. Implications of TNF Signaling
Persistently elevated levels of TNF are evident in chronic inflammatory disorders, e.g.,
rheumatoid arthritis (RA), inflammatory bowel disease (IBD), ankylosing spondylitis (AS) and
psoriasis. TNF regulates differentiation, proliferation and apoptosis of several non-immune cells
such as IECs, keratinocytes or synovial fibroblast [80–82]. In IBD, overexpression of TNF may
contribute to increased barrier permeability for luminal pathogens [81]. Importantly, TNF can also
initiate necroptosis and this is a common feature in the pathology of several inflammatory diseases
and autoimmunity such as in Crohn’s disease (CD) [21–23]. The pro-inflammatory role of TNF in
these autoimmune diseases is supported by the great clinical effects of TNF-antagonists, which are
used in these disorders both in humans as well as in animal models of for instance RA [83,84].
Again, genetically modified mice were an invaluable tool to elucidate the pathogenic role of TNF
here. Many valuable insights came from transgenic mice that lack the AU-rich element (ARE) in the
3′-untranslated region of the TNF mRNA. TNF∆ARE mice systemically overexpress TNF due to the
increased stability of its mRNA. They spontaneously develop erosive, symmetric polyarthritis and
IBD. As the clinical symptoms in the mice resemble the clinical and histopathologic features of RA
and IBD in patients, they are an ideal model for these diseases [30,85]. Furthermore, other transgenic
mice expressing a hTNF transgene were found to develop a TNF-dependent chronic inflammatory
polyarthritis resembling human RA [86,87]. However, this does not necessarily mean that all types of
RA and IBD in patients start with a dysregulated TNF expression.
Despite the untoward effect of TNF in the development of autoimmunity, it has also been
demonstrated that TNF is sometimes needed to inhibit or control autoimmunity [88]. Indeed,
TNF neutralization exacerbates acute injury in the dextran sodium sulfate (DSS) colitis mouse
model [89] and exogenous TNF administration could alleviate colitis in oxazolone-treated mice and
attenuate the disease severity in RA [90,91]. Furthermore, studies demonstrate that chronic treatment
with a low TNF dose or local pancreatic expression of TNF in adult non-obese diabetic (NOD) mice,
which is a model for diabetes, delayed spontaneous development of type I diabetes in these mice [92,93].
A similar finding was done in NZB/W mice, a model for systemic lupus erythematosus (SLE), in the
development of autoimmunity [94]. Additionally, when these lupus-prone mice were crossed into
a TNF deficient background, they experienced aggravated disease [95]. In addition to suppressing
systemic autoimmunity, TNF can also suppress organ-specific autoimmunity. The importance of
this mechanism is further highlighted in MS mouse models. In the absence of TNF, myelin-specific
deleterious T cells remain abnormally prolonged self-reactive to myelin, while in normal conditions
they become inactivated [96]. Therefore, TNF may be protective against chronic experimental
autoimmune encephalomyelitis (EAE) by downregulation or inactivation of the potentially detrimental
autoimmune T cell response against myelin antigens [88]. In conclusion, many models suggest an
immunosuppressive and immunoregulatory role for TNF, which may segregate at the level of the two
different receptors: the classic pro-inflammatory activities of TNF mediated by TNFR1 may account
for chronic inflammatory pathology and tissue damage, especially in situations with persistent and
maintained TNF overexpression [88], while immunosuppressive activities might be attributed to
TNFR2 [97].
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3.3.2. Receptor-Dependent Roles for TNF in Autoimmunity
To analyze the contribution of the two TNF receptors, the aforementioned experimental mouse
models were applied in a TNFR1 and/or TNFR2 KO background. In the collagen-induced arthritis
(CIA) model for RA, TNFR1 KO mice developed the disease at lower incidence and in a milder
form than WT mice [83,98]. In contrast, TNF-driven arthritis was severely aggravated in TNFR2
KO mice [35,99]. The importance of TNFR2 signaling in autoimmune diseases is also illustrated by
its prominent role in regulatory T cell (Treg) functioning [100–102]. The most potent Tregs express
the highest TNFR2 levels and TNF/TNFR2 signaling is required to activate and expand naturally
occurring Tregs [101,103,104]. Given that Tregs are essential for immune tolerance and suppress
self-reactive T cells [105], their optimal functioning should be considered in new therapies. In RA,
selective inhibition of TNFR1 abrogates inflammation by enabling Tregs to suppress IL-17 production,
and promotes Treg activity via TNFR2 signaling [106,107]. Likewise, TNFR1 or double TNFR
deficient TNF∆ARE mice had a normal histology without any sign of macroscopic illness. In contrast,
symptoms were not improved but rather aggravated with more aggressive and destructive arthritis
when crossed into the TNFR2 KO background [85]. In addition to these data, mouse and human
data in CD point to the importance of the suppressive functions of Tregs which are attributed to
TNFR2 [108,109]. Indeed, in mice, Tregs are critical for maintaining intestinal tolerance to luminal
antigens and for preventing intestinal inflammation [110]. Genetic data further strengthen the
importance to acknowledge the two receptors separately. Indeed, polymorphisms in (the promoter
region of) TNFSF1B were associated with increased susceptibility for patients to develop RA, IBD or
lupus, suggesting that TNFR2 mutations could lead to increased inflammation due to defective control
mechanisms [111,112]. However, the effects of these polymorphisms on the Treg population are not
studied and require further examination [113].
3.4. The Role of TNF in Neurodegenerative Diseases
The most under-appreciated role of TNF is its role in neurobiology. In the last decades, TNF has
been shown to have several important physiological but also pathological functions in the CNS [12].
In the brain, the duality of TNF is nicely demonstrated at several levels. On the one hand,
TNF functions as an essential gliotransmitter, secreted by neurons and glial cells such as microglia
and astrocytes. Moreover, TNF regulates synaptic communication between neurons as demonstrated
by its involvement in synaptic scaling and plasticity [114], and it orchestrates learning and memory
processes via hippocampal neuronal development [115]. Other neurophysiological functions of TNF
are listed by Decourt et al. [116]. On the other hand, TNF potentiates excitotoxicity via a microglial and
astroglial loop that ultimately results in neuronal death, and inhibition of sTNF ameliorates synaptic
dysfunction in aging and improves learning [117]. Conversely, TNF also protects against excitotoxicity
via TNFR2 [12,118,119].
Intriguingly, systemic inflammation induces TNF expression in the brain [120] and it has been
shown that in mice, TNF can cross the blood–brain barrier (BBB) to reach the brain via a saturable
transport system [121]. Microglia which are the tissue-resident macrophages of the CNS are one of the
major producers of TNF, participating in numerous pathophysiological conditions in the brain. Indeed,
elevated TNF levels are evident in many neurological disorders such as in affected areas in multiple
sclerosis (MS, cf. Section 3.4.2), Alzheimer’s disease (AD, cf. Section 3.4.3), Parkinson’s disease
(PD, cf. Section 3.4.4), stroke and traumatic brain injury (TBI). Intriguingly, TNF, amongst others,
mediates necroptosis which is clearly involved in AD and PD, highlighting one of the possible
detrimental effects TNF can exert in these disorders [122]. TNF released in the brain can be both
toxic and tropic; however, this is not always clear and depends on the context [12,123,124]. Therefore,
unselective targeting of TNF in the brain with therapeutics is not desirable and distinctions should be
made based on its function.
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3.4.1. Differential Roles of TNFR1 and TNFR2 in Neuronal Health and Disease
In the CNS, microglia secrete TNF and it has been shown that TNF promotes its own release
via TNFR1. Hence, it sustains a vicious feedback loop in microglial activation [125]. Additionally,
TNFR1 signaling upon TNF interaction could induce the release of glutamate from microglia and
astrocytes and also directly potentiates glutamate excitotoxicity through the activation of the glutamate
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors [125–127]. Conversely,
TNFR2 activation protects against glutamate-induced excitotoxicity [119,128]. In aging, it has
been suggested that TNF/TNFR1 signaling contributes to cognitive decline through its effects on
hippocampal long-term depression (LTD). Indeed, in aged rats, the hippocampal levels of the TNF
receptors are changed in favor of TNFR1, and inhibition of the TNF/TNFR1 pathway improves
behavioral performances and synaptic functioning [117]. Literature also suggests a direct link between
the activation of TNFR1 by TNF and neuronal apoptotic death in neurodegenerative disorders [129,130].
Additionally, neurons lacking TNFR2 are more vulnerable to TNF-induced cell death than WT neurons,
as TNFR2 overrides the death signals delivered through TNFR1 [131]. In a disease state, TNF robustly
stimulates TNFR1 resulting in an apoptotic signal that overweighs the signals through TNFR2. In this
respect, hippocampal neurons from TNFR2−/− mice are more vulnerable to a low TNF dose whereas
TNF has little effects in TNFR1−/− hippocampal neurons [130]. During neurogenesis, TNF via TNFR1
negatively impacts the hippocampal neurogenesis but is essential for striatal morphology and injury
resolution. Conversely, TNFR2 is required for normal hippocampal neurogenesis and morphology
in healthy adults, and for hippocampal healing upon injury [132–135]. In addition, in the context of
neuropathic pain, the induced depression and impaired hippocampal plasticity depend on TNFR1
signaling [136]. During stroke, optimal TNF signaling is pivotal for hippocampal neurogenesis,
functioning and repair following ischemic insults [137,138]. Table 1 provides a non-exhaustive list of
neurological conditions in which different roles for TNFR1/2 are described, and we will deeper dig
into MS, AD and PD.
3.4.2. TNF and Its Receptors in Multiple Sclerosis
MS is characterized by immune cell infiltration and upregulation of pro-inflammatory cytokines
and chemokines such as IL-1β, IL-17, IL-22, IFN-γ and TNF in CSF [139,140]. An important role for
TNF in MS has been described although its exact role remains inconclusive. TNF and its receptors are
found in the serum, CSF and lesions of MS patients and TNF levels in serum and CSF are correlated
with disease severity [140,141]. Additionally, mouse studies using the established MS mouse model
EAE revealed a pathogenic role for TNF in MS [142,143] and CNS-specific overexpression of TNF leads
to spontaneous demyelination [144,145]. It has been suggested that TNF-mediated demyelination
depends on cellular contacts between TNF-producing cells such as astrocytes or microglia and
oligodendrocytes (OLGs). Indeed, human tmTNF expressed by astrocytes is more effective to kill OLGs
than sTNF and astrocyte-specific overexpression of tmTNF triggers inflammation and demyelination
and this is mediated via TNFR1 [145,146]. It was shown that T cells and myeloid cells are the
critical cellular sources of TNF during EAE as T cell-derived TNF determines the severity in EAE by
regulating leukocyte influx into the CNS, whereas myeloid-derived TNF controls the early expression of
cytokines and determines the onset of EAE [147]. Evidence of its pathogenic role was further provided
by anti-TNF treatment that prevented the initiation of clinical symptoms in EAE and ameliorated
progression in established disease in mice [148]. To the contrary, although initiation of EAE in TNF
KO mice was delayed, the mice eventually developed EAE that was as severe or even more severe
with high mortality and extensive inflammation as compared to WT mice [149–151]. Furthermore,
anti-TNF treatment increased MRI activity and immune activation in several patients with primary
progressive MS (PPMS) [152] and in patients with relapsing-remitting MS (RRMS), a phase II clinical
study with a TNF inhibitor (Lenercept, a dimeric TNFR1 fused to the immunoglobulin (Ig)-G1 heavy
chain) was discontinued because of unexpected exacerbations of the disease [153]. Strikingly, anti-TNF
medication can even sporadically induce demyelinating diseases and neuropathies (cf. Section 4.3.4),
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and several groups found that TNF expressed in lymphoid organs could dampen the immune response
by inhibiting the development of encephalitogenic T cells responses [96,147]. Contrasting results have
also been described in OLGs as TNF is involved in oligodendrocyte precursor cell (OPC) proliferation
and maturation [33] but also causes OLG cell death both in vitro and in vivo [154–157]. OLGs located
at the edge of active lesions express both TNFRs and this could explain the duality of TNF in MS.
These results suggest that TNF is again not only destructive but also has essential roles to maintain
immune homeostasis in the CNS environment.
Interestingly, the TNFRSF1A locus has been validated as a MS susceptibility locus [158]. The disease
genetic variant leads to the expression of a soluble form of TNFR1 that sequesters TNF and thereby
abrogates signaling through TNFR2. This suggests that dysregulation of the TNF/TNFR1-pathway
has a role in the onset of MS [159]. TNF/TNFR1 signaling has been shown to be involved in
OLG apoptosis, demyelination, and initiation of inflammatory processes (Figure 2 and Table 1).
First evidence of the harmfulness of TNFR1 has been delivered as EAE disease development was
prevented in double TNFR KO as well as in TNFR1 KO mice. This was contrasted by the outcome
of TNFR2 null mice which developed a more severe and chronic disease [160,161]. Interestingly,
both TNFR1 and TNFR2 KO mice were able to suppress the anti-myelin reactivity, leading to the
idea of redundancy in the immunosuppressive functions of the two receptors. However, again,
TNFR1 was found to be responsible for the detrimental signals, while mainly TNFR2 was essential
for resolving the inflammation and initiating repair [161]. Additionally, in TNFR1 deficient mice that
locally express TNF by CNS glial cells, it has been shown that this receptor was able to induce OLG
apoptosis, primary inflammatory demyelination and the generation of MS-like plaques [157]. Moreover,
EAE mice that only express non-cleavable tmTNF were protected against EAE, suggesting that the
interaction between sTNF and TNFR1 mediates the pathology [162]. This concept was further
supported by the observation that inhibition of sTNF reduced spinal cord injury [163] and EAE
pathology, associated with reduced immunoreactivity, increased expression of neuroprotective
and myelin-specific genes and axonal preservation [164–166]. Although sTNF inhibition did not
prevent OLG loss and demyelination in the cuprizone-induced demyelination model, it induced
early remyelination due to improved removal of myelin debris by CNS phagocyting macrophages,
indicating that sTNF inhibits the remyelination process [167]. Furthermore, astrocyte-expressed TNF is
crucial for blood–brain barrier (BBB) damage and endothelial activation via TNFR1 [114,145,157].
Interestingly, TNFR1 neutralization may indirectly stimulate TNF/TNFR2 signaling in the EAE
lesions and promotes remyelination in chemically-induced demyelination [168]. Others successfully
applied specific TNFR1 inhibition in EAE using the TNFR1-selective antagonistic mutant TNF protein,
PEG-R1antTNF [169] or the commercial monoclonal hamster IgG antibody against mouse TNFR1 [170].
Our research group developed a trivalent TNFR1 Nanobody with very promising characteristics in the
EAE pathology [171] (cf. Section 6). MS often presents with memory deficits, and it has been elegantly
shown that TNF/TNFR1 signaling in astrocytes is responsible for these cognitive disturbances [172].
However, this symptom has never been therapeutically addressed in mouse studies and the efficacy
of TNFR1-inhibiting drugs to overcome memory deficits in MS should definitely be investigated in
future research.
TNFR2 is minimally expressed in the CNS in physiological conditions but its expression is boosted
in neurological condition in glial cells such as microglia, astrocytes and OLGs [173] but usually not in
neurons. In MS, microglia, monocytes and macrophages express TNFR2 and these cell populations
also play pivotal roles in the disease [165]. Moreover, TNFR2 null mice subjected to MOG35–55-induced
EAE showed exacerbated disease, enhanced Th1 cytokine production, and enhanced CD4+ cell
infiltration in the CNS [161]. Conversely, mice only expressing tmTNF (i.e., TNF non-sheddable mice),
which mainly signals via TNFR2, were protected during EAE [162]. A neuroprotective role is attributed
to TNFR2 because its signaling pathway protects neurons against excitotoxic insults in vitro and in vivo
induced by excessive glutamate levels [128,174], and against oxidative stress [168,175]. Furthermore,
TNFR2 promotes neuronal survival, OPC maturation and differentiation, OLG proliferation and
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CNS remyelination [33,168,176–179]. Given that TNFR2 is also important for Treg expansion and
facilitates their suppressive capacity against effector T cells, and since certain Tregs are dysfunctional in
MS [180], TNFR2′ optimal signaling should be guaranteed. Intriguingly, it has been shown that also
TNFR2 on non-hematopoietic cells is important to modulate the fate of Tregs and their suppressive
functions [181]. However, TNFR2 has a dichotomous function: Gao et al. recently showed that
peripheral macrophage/monocyte-TNFR2 drives the immune activation via T cell activation and
triggers leukocyte transmigration across the BBB, whereas microglial TNFR2 provides protective
signals by promoting anti-inflammatory pathways [173,182]. This should be considered for therapeutic
purposes. The complexity is even increased as TNF mediates regression of activated myelin-specific
T cells. This prevents prolonged primary myelin reactivity and limits the probability for chronic
disease. Although it was first thought that this was mediated by TNFR1, more recent studies pointed
towards TNFR2, but also redundancy in this immunosuppressive function is described for the two
receptors [88,96,183,184].
Table 1. Evidence for specific TNF(R) targeting in neuronal disease.
Model In Vivo/In Vitro Mechanism References
Multiple Sclerosis
TNFR1/TNFR2−/−, TNFR1−/−,
TNFR2−/− in EAE
In vivo
TNFR1−/− mice are resistant to disease development [160,161,171]
TNFR2−/− mice display exacerbated disease
progression
TNF−/− and TNFR1−/− mice in EAE In vivo
TNF protects against EAE chronicity by inducing
regression of myelin-reactive T cells, independent of
TNFR1
[96]
TNF∆1–12 mice in EAE In vivo tmTNF protects against disease development [162]
TNFR2−/− in EAE and bone-marrow
transplantations
In vivo TNFR2 on non-hematopoietic cells is required for Tregfunctioning [181]
OLG-specific TNFR2 KOs (CNP-cre
TNFR2fl/fl) in EAE In vivo OLG-TNFR2 drives OPC differentiation [177]
CX3cr1-cre TNFR2fl/fl and LysM-cre
TNFR2fl/fl in EAE
In vivo
TNFR2 ablation in microglia leads to early EAE onset
[173]TNFR2 ablation in monocytes results in EAE
suppression
TNFR1−/− that conditionally
re-express TNFR1 in astrocytes in EAE
(hGFAPcreT2/tnfr1cneo/cneo)
In vivo Astrocyte TNFR1 mediates learning memoryimpairment [172]
TNF−/−, TNFR1−/− and TNFR2−/− in
CPZ model
In vivo TNFR2 is critical for OLG proliferation andremyelination [33]
TNFR2−/− in CPZ model In vivo Astrocyte TNFR2 mediates OPC proliferation anddifferentiation via CXCL12 [179]
CNS-overexpressing TNF mice in
TNFR1 or TNFR2 KO background In vivo TNFR1 induces OLG apoptosis [157]
Neuron or astrocyte-overexpressing
tmTNF mice In vivo
Astrocyte tmTNF but not neuron-specific TNF triggers
CNS inflammation and neurodegeneration [145]
TNFR1 inhibition in EAE In vivo Disease development is reduced [169,170]
Nanobody-based TNFR1 inhibition in
EAE In vivo
Prophylactic and therapeutic administration prevents
or stops disease development [171]
sTNF inhibition in EAE In vivo Functional outcome is improved [165]
sTNF inhibition in EAE and in
astrocyte-neuron coculture
In vivo tmTNF is neuroprotective via NF-κB
[164]In vitro sTNF inhibition protects against glucose deprivation
sTNF inhibition in CPZ model In vivo tmTNF is neuroprotective and is needed to maintainmyelin sTNF inhibits remyelination and repair [167]
Astrocytes-OPC co-culture In vitro Astrocyte TNFR2 promotes OLG maturation via LIF [178]
Rat microglia and OLG In vitro tmTNF kills OLGs more efficiently than sTNF [146]
Alzheimer’s Disease
5xFAD/Tg197 mice In vivo
Peripheral hTNF mediates reduced amyloidosis and
more microglial and astrocytic activation, but also
synaptic loss
[185]
TNFR1-overexpressing primary
neurons and TNFR1−/− neurons In vitro TNFR1 mediates Aβ-induced neuronal death [129]
APP/PS1 TNFR1−/− and icv AβO
injection in TNFR1−/− In vivo
TNFR1 mediates AD-mediated choroid plexus
inflammation and TNFR1+/+ mice are protected
against cognitive decline, microgliosis and amyloidosis
[186]
APP23 TNFR1−/− In vivo
TNFR1 signaling enhances BACE1 activity and Aβ
production. Absence of TNFR1 leads to less memory
deficits, neuronal loss and microglia activation
[131]
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Table 1. Cont.
Model In Vivo/In Vitro Mechanism References
APP23 TNFR2−/− In vivo Exacerbated AD pathology [187]
Nanobody-based TNFR1 inhibition icv
AβO injection In vivo TNFR1 inhibition prevents against cognitive decline [186]
sTNF inhibition in 3×Tg-AD mice In vivo sTNF inhibition reduces APP accumulation inhippocampus and restores synaptic dysfunction [188,189]
TNFR2 inhibition in SH-SY5Y cells In vitro Enhances Aβ toxicity [190]
Neuronal TNFR2 knockdown in
3×Tg-AD mice In vivo Enhances Aβ and Tau-pathology [191]
Transverse hippocampus slices of WT
or TNFR1−/− mice In vitro
TNF via TNFR1 is a critical mediator of the
Aβ-induced inhibition of LTP [192]
Parkinson’s Disease
Double TNFR−/− mice in MPTP model In vivo Mice were protected against neurotoxicity, buthippocampal vulnerability increased [193,194]
TNFR1−/−, TNFR2−/− mice in MPTP
model
In vivo Neither TNFR1 nor TNFR2 KO mice were protectedagainst MPTP neurotoxicity [195]
sTNF neutralization in 6-OHDA model In vivo Reduced nigral dopaminergic loss and microgliaactivation [196–198]
Spinal Cord Injury and Traumatic Brain Injury
sTNF inhibition in SCI In vivo Protective [163]
Double TNFR−/− mice subjected to TBI In vivo Bigger lesion volume and BBB impairment [199]
TNFR1−/− and TNFR2−/− subjected to
controlled cortical impact brain injury
In vivo TNFR1 exacerbates cognitive functioning, TNFR2attenuates it [200]
TNFR1−/− and TNFR2−/− subjected to
TBI
In vivo TNFR1 exacerbates neurobehavioral deficits and tissuedamage, TNFR2 is protective [201]
Stroke, Ischemia and Oxidative Stress
Double TNFR−/− mice in stroke model In vivo More neuronal damage and less injury-inducedmicroglial activation [138]
TNFR1−/−, TNFR2−/− and double
TNFR mice in focal cerebral
ischemia/reperfusion
In vivo TNFR1 limits neuronal damage and preventshippocampal degeneration [202]
TNFR1−/− and TNFR2−/− in model
retinal ischemia
In vivo TNFR1 augments neuronal death, TNFR2 promotesneuroprotection via PI3K-PKB/Akt pathway [203]
TNFR2 agonist in LUHMES cells
treated with H2O2
In vitro TNFR2 promotes anti-apoptotic response viaPI3K-PKB/Akt pathway [168]
hTNFR2-expressing OLG + TNFR2
agonist treated with H2O2
In vitro TNFR2 protects OPC against oxidative stress [175]
Excitotoxicity and Seizures
TNFR2 agonism or TNFR1 inhibition in
NMDA-induced neurodegeneration In vivo
TNFR1 inhibition/TNFR2 agonism protects
cholinergic neurons against cell death and reverts
neurodegeneration-associated memory impairment
[174]
TNFR1−/− and TNFR2−/− mice on
kainate seizures
In vivo TNFR2 exerts anticonvulsant effects, TNFR1 mediatesexcitotoxicity [204]
Primary cortical cells treated with
glutamate In vitro
TNFR2 protects neurons against excitotoxic insults via
activation NMDA-receptor [128]
Microiontophoretic administration of
glutamate to TNFR1−/− or TNFR2−/−
mice
In vitro TNFR2 protects hippocampal neurons againstexcitotoxicity [205]
Brain Inflammation
Hippocampal TNFR1−/− and
TNFR2−/− neurons In vitro
TNF vulnerability of TNFR2−/− hippocampal neurons
is higher than of TNFR1−/− neurons [130]
Cultured microglia In vitro
TNFR2 upregulation after inflammatory stimuli and
TNFR2-mediated induction of anti-inflammatory
pathways
[182]
Neuropathic Pain and Hippocampal Neurogenesis
Healthy or diseased TNFR1−/− and
TNFR2−/− mice In vivo
TNFR1 is a suppressor of adult neurogenesis, absence
of TNFR2 leads to reduced hippocampal
neurodegeneration
[132–135]
TNFR1−/− and TNFR2−/− mice
subjected to CCI
In vivo TNFR1 induces a neuropathic-pain induceddepression [136]
Double TNFR mice and TNFR1 and
TNFR2 inhibitors following CCI In vivo
TNFR1 inhibition prolongs Wallerian degeneration
and TNFR1 regulates macrophage influx [206,207]
TNFR1 mediates thermal hyperalgesia
AβO: oligomerized amyloid beta; AD: Alzheimer’s disease; APP/PS1: amyloid precursor protein/presenilin 1;
BACE1: beta-secretase 1; CCI: chronic constriction injury; CNP: 2′,3′-cyclic nucleotide 3′-phosphodiesterase; CPZ:
cuprizone; CXCR3: CXC motif chemokine receptor 3; EAE: experimental autoimmune encephalomyelitis; icv:
intracerebroventricular; KO: knockout; LIF: leukemia inhibiting factor; LTP: long term potentiation; LUHMES:
Lund human mesencephalic; LysM: lysin-motif; NMDA: N-methyl-D-aspartate; MPTP: 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine; OLG: oligodendrocytes; OPC: oligodendrocyte precursor cells; PI3K-PKB/Akt:
phosphoinositide-3-kinase–protein kinase B/Akt; SCI: spinal cord injury; sTNF: soluble TNF; TBI: traumatic
brain injury; Tg: transgenic; tmTNF: transmembrane TNF.
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Figure 2. Multiple roles for tumor necrosis factor (TNF) receptor (TNFR) signaling in multiple 
sclerosis (MS) pathology. In the central nervous system (CNS), TNF is primarily expressed by 
astrocytes, microglia and neurons and can stimulate its own release via TNFR1. A detrimental role 
for TNFR1 has been described in the pathology of MS. TNFR1 signaling triggers oligodendrocyte 
(OLG) death and contributes to primary demyelination via macrophages. Conversely, TNFR2 has 
protective effects in the CNS, as the interaction with tmTNF on astrocytes stimulates remyelination 
and neuronal TNFR2 protects against excitotoxicity. In the periphery, TNFR2 induces the 
development of effector T cells, but in the CNS, microglial-expressed TNFR2 is protective. TNF, 
possibly via TNFR2, mediates regression of activated myelin-specific T cells. Furthermore, TNFR2 
signaling also facilitates the expansion of regulatory T cells (Tregs) and improves their suppressive 
capacities against effector T cells. Normal arrows indicate the action of a mediator or the processes 
that are induced; bold arrows represent mediators produced by a specific cellular subset. T bars 
represent the inhibition of the indicated pathway. 
TNFR2 is minimally expressed in the CNS in physiological conditions but its expression is 
boosted in neurological condition in glial cells such as microglia, astrocytes and OLGs [173] but 
usually not in neurons. In MS, microglia, monocytes and macrophages express TNFR2 and these cell 
populations also play pivotal roles in the disease [165]. Moreover, TNFR2 null mice subjected to 
Figure 2. Multiple roles for tumor necrosis factor (TNF) receptor (TNFR) signaling in multiple
sclerosis (MS) pathology. In the central nervous system (CNS), TNF is primarily expressed by
astrocytes, microglia a neurons and can stimulate its own release via TNFR1. A detrimental role
for TNFR1 has been described in the pathology of MS. TNFR1 signaling triggers oligodendrocyte
(OLG) d ath and contributes to primary demyelination via m c phages. Conversely, TNFR2 has
protective effects in the CNS, as the interaction with tmTNF on astrocytes stimulates remyelination and
neuronal TNFR2 protects against excitotoxicity. In the periphery, TNFR2 induces the development of
effector T cells, but in the CNS, microglial-expressed TNFR2 is protective. TNF, possibly via TNFR2,
mediates regression of activated myelin-specific T cells. Furthermore, TNFR2 signaling also facilitates
the expansion of regulatory T cells (Tregs) and improves their suppressive capacities against effector
T cells. Normal arrows indicate the action of a mediator or the processes that are induced; bold arrows
represent mediators produced by a specific cellular subset. T bars represent the inhibition of the
indicated pathway.
See Table 1 and Figure 2 for the involvement of the two TNFRs in neurodegenerative diseases.
Collectively, one can say that sTNF/TNFR1 inhibits remyelination, whereas tmTNF directly signals
through TNFR2 expressed on OPCs or macrophages to mediate remyelination and to protect
against damage.
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3.4.3. TNF Involvement in Alzheimer’s Disease
As already outlined in the previous sections, TNF has a very important pluripotent role in the
brain. The clinical involvement of TNF in AD is evidenced by the observation that TNF serum and
CSF levels are correlated with disease severity and that TNF co-localizes with amyloid beta (Aβ)
plaques in the brain. In transgenic mouse models of AD, TNF contributes to disease progression
and onset [12]. However, TNF is also a known regulator of synaptic communication between cells.
Clearly, the role of TNF in the brain is divergent: low levels of TNF are needed in healthy brains,
while overexpression of TNF, primary by microglia, is neurodegenerative. It has been proposed that
the synaptic effects of TNF are associated with the synaptic dysfunction that has a central role in
AD, particularly with respect to cognitive dysfunction [208]. Indeed, TNF can influence synaptic
transmission and plasticity such as hippocampal long-term potentiation (LTP) and synaptic scaling
that contributes to early memory loss and learning impairment [192,209,210]. Additionally, it has been
demonstrated that TNF contributes to amyloidogenesis, although there is no clear consensus where
TNF interferes in the amyloidogenesis process. A study in TNF KO AD mice (5×FAD) found that the
diminished amount amyloid plaques and Aβ species are a result of reduced Aβ generation and not a
consequence of more clearance [211]. Others state that TNF is implicated in both Aβ generation and
clearance [211,212]. TNF, whether or not produced by neurons, promotes the expression of astrocyte
beta-secretase 1 (BACE1) and suppresses Aβ clearance by inhibiting microglial phagocytosis [212–214].
In contrast, transient hippocampal TNF expression decreases Aβ disposition [215]. In further support
of the neurotoxicity of TNF in AD, chronic neuronal TNF overexpression promotes brain inflammation
and is detrimental for neuronal viability and these inflammatory events coincides with the appearance
of cognitive deficits and synaptic dysfunctions [216]. This suggests that TNF participates in multiple
stages of AD pathology [216] (Table 1). Clearly, TNF has again both beneficial and detrimental roles in
AD, depending on differences in the (spatiotemporal) TNF expression pattern.
Epidemiological studies demonstrate that the relative AD risk was significantly reduced in RA
patients that received the anti-TNF drug etanercept [217,218]. To better understand the contribution of
peripheral TNF-mediated inflammation to AD pathology, Paouri et al. crossed AD susceptible mice
(5xFAD) with Tg197 mice that have a whole-body expression of hTNF. Interestingly, peripheral hTNF
which signals only via mouse TNFR1 [219], robustly activates microglial and astrocytes which in turn
clear Aβ but also mediate synaptic loss [185]. Despite of this evidence, preclinical studies in mouse
AD models with anti-TNF inhibitors left us with conflicting results. In some studies, the use of TNF
inhibitors such as etanercept or infliximab demonstrated clinical benefits [220,221], whereas other
failed to reproduce that [222,223]. In addition, results from clinical studies are not always clear:
a double-blind randomized trial of peripheral administration of etanercept failed to show cognitive or
behavioral benefits [224], whereas perispinal administration of etanercept improved cognitive decline
in a small short-term pilot study [225,226]. Intrathecal infliximab administration also improved the
cognitive behavior, but this was a case report in one woman thus larger studies are imperative [227].
Recently, a phase I open-label crossover study in patients with mild to moderate AD treated with
perispinal administration of etanercept together with dietary supplements could provide more insights
into the potential effect of etanercept in AD but unfortunately, results were not conclusive about the
cognitive benefit compared to patients treated with nutritional supplements alone [228]. These clinical
and preclinical data might indicate that the therapy needs to be initiated at very early stages of
AD, rather than in advanced disease, or that a more selective TNF neutralizing approach should
be implemented.
In AD brains, TNFR1 protein levels and TNFR1 binding affinity were augmented in contrast
to TNFR2 levels and binding affinity compared to non-demented patients [229,230]. Interestingly,
our research team found that in the choroid plexus of AD patients, TNF is the main inflammatory
upstream mediator, providing detrimental signals via TNFR1. The blood–CSF barrier consists of a
monolayer of choroid plexus epithelial cells, and we found that TNFR1 contributes to the morphological
damage which is typically seen in the choroid plexus of AD patients [186,231]. Additionally, Li et al.
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reported that Aβ induces neuronal death via TNFR1 in the AD brain [129] and TNFR1 contributes to
the amyloidogenesis via the regulation of BACE1 in APP23 transgenic mice [131]. Our recent study
reinforces these results in two AD model: the intracerebroventricular (icv) injection of oligomerized
Aβ and in APP/PS1 mice [186]. Our results were in line with observations in APP23 mice devoid of
TNFR1 that have less memory deficits, neuronal loss and microglia activation compared to normal
APP23 mice [131]. Pharmacological evidence was also provided as inhibition of sTNF, signaling
through TNFR1, reduced the accumulation of APP fragments in hippocampus and cortex of 3×Tg-AD
mice, and restored synaptic dysfunction and LTP impairment in 5xFAD mice [188,189]. These results
were in agreement with the study of Paouri et al. [185]. Strikingly, direct TNFR1 blockage with
a TNFR1-inhibiting Nanobody TROS alleviated the AβO-induced memory deficits [186] and the
Aβ-mediated inhibition of hippocampal LTP is reversed in absence of TNFR1, providing strong
evidence that TNFR1 activation is required for the Aβ-mediated inhibition of LTP [192]. Conversely,
inhibition of TNFR2 increased Aβ toxicity in vitro [190] and APP23 mice deficient for TNFR2 displayed
exacerbated AD pathology compared to APP23 mice with a functional TNFR2 gene [187]. Furthermore,
selective inhibition of neuronal TNFR2 enhanced the Aβ and Tau-related pathologic features in AD
and diminished microglia activation needed for Aβ clearance [191]. These observations support
the idea that TNFR1 has detrimental roles in AD, whereas TNFR2 needs to be spared to counteract
the Aβ-mediated pathology and urges more selective targeting of the TNF pathway (see Table 1).
Likewise, in seizure models, TNFR2 is important to protect hippocampal neurons against excitotoxicity
and pan-TNF inhibitors that do not spare TNFR2 lead to untoward effects in this brain region,
again suggesting that TNFR2 is important in hippocampal repair and neurogenesis [205].
3.4.4. TNF in Parkinson’s Disease
Inflammatory processes are described in PD patients and some may argue that they even trigger
the disease onset. This also accounts for peripheral inflammation that enhances the degeneration
of dopaminergic neurons. This was clear in animal models, but also human data point in that
direction [232]. As in several other neurological disease, increased levels of TNF and sTNF(R1) are
evident in the CSF and tissues of PD patients, as well as in postmortem brain tissue. The levels found
in serum correlated with disease severity according to some researchers [124,233]. One group also
found that TNF gene promoter polymorphisms were associated with an earlier age of PD onset [234].
This evidence about the effector role of TNF in PD is strengthened by the observation of very quick
fundamental TNF increments in PD mouse models. In addition, TNF was found to be extremely toxic
for dopaminergic neurons in vitro. These findings support the idea that the TNF-driven inflammation
is essential in the pathogenesis and progression of the disease [12]. Unfortunately, studies in
transgenic mice that were subjected to different PD models (injection of parkinsonian neurotoxic
agents 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)) have
yielded contrasting results. The toxicity of TNF on dopaminergic neurons was demonstrated in
TNF KO mice which were less sensitive to MPTP-induced striatal dopaminergic neurotoxicity [235].
As dopaminergic neurons were shown to express TNFR1 and this expression is induced in PD [236],
the role of the two receptors was further investigated by several groups. In line with the results obtained
in the TNF KO mice, also the double TNFR KO mice were completely protected against MPTP-induced
neurotoxicity by suppressing microglial activation [193,194,237]. However, this was rebutted by Leng
et al., stating that TNF has protective effects, mediated by TNFR-independent mechanisms [195].
Because the vulnerability of hippocampal neurons to MPTP was increased in mice lacking the two
TNFR, a dual and region-dependent role of TNF was proposed and this highlighted the neurotrophic
or neuroprotective role of TNF in the hippocampus [194]. This specific role was confirmed by others
that observed that TNF does not participate in dopaminergic neuronal cell death in PD but rather alters
dopamine metabolism and the survival of dopaminergic terminals [238]. Interestingly, the effects of
TNF are not only region-dependent but also dose-dependent: low TNF concentrations in the substantia
nigra mediate neuroprotective effects in mice by reducing the nigrostriatal neurodegeneration induced
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by 6-OHDA although chronic expression of low TNF levels eventually causes dopaminergic cell
death, and functionally leads to akinesia. Conversely, high TNF levels induce progressive neuronal
cell loss accompanied by gliosis and inflammation [239,240]. In addition, in preclinical studies,
contradictory results were obtained as early TNF blockage worsened the outcome after intrastriatal
6-OHDA injection [241] but intranigral infusion of sTNF neutralizing therapeutics attenuated the
nigral dopaminergic loss and microglia activation [196–198]. This sTNF inhibitor could cross the
BBB and had disease-modifying properties upon peripheral administration [198]. Inhibition of
TNF synthesis by thalidomide partly protected against MPTP-induced dopamine depletion [235].
Interestingly, a BBB-penetrating Trojan horse has been designed consisting of a TNF decoy receptor
fused to a mAb against the mouse transferrin receptor (TfR). This drug was neuroprotective in the
6-OHDA mouse model of PD. In contrast, etanercept that does not penetrate the BBB had no effect
on the neurobehavior [242]. To analyze and interpret these incoherent results, one should account
for the divergence across all studies, with differences in model, doses and timing of analysis [243].
Furthermore, these models are difficult to extrapolate to human situations as the TNF peak in these
mouse models is relatively short, whereas the levels remain elevated along the disease course in
PD patients.
4. TNF Inhibitors
4.1. Approved TNF Inhibitors
The initial concept to use recombinant TNF as an anti-tumor agent was quickly followed by the
idea to consider TNF as a drug target for inflammatory diseases [244]. Indeed, TNF represents an active
and attractive objective for drug development despite the initial skepticism because of the failure of
anti-TNF drugs in sepsis patients [245,246]. The rationale to target TNF was first confirmed in a murine
RA model [247], and, in 1993, RA patients were successfully treated with mAb cA2, later known
as infliximab [248]. This success was the start to further develop anti-TNF drugs in TNF-involving
inflammatory diseases. Currently, five anti-TNF biologics and in total 25 drugs that inhibit or modulate
the effects of TNF, are approved for clinical use by the Food and Drug Administration (FDA) and
European Medicines Agency (EMA) for the treatment of RA, AS, psoriasis and psoriatic arthritis
(PsA), juvenile idiopathic arthritis (JIA), CD and ulcerative colitis (UC). Recently, adalimumab was
also licensed in some countries to treat uveitis and hidradenitis suppurativa which is a chronic skin
disease characterized by recurrent abscesses. Furthermore, there is off-label use in Behcet’s syndrome
and amyloidosis [245,249]. The introduction of TNF inhibitors on the market has revolutionized
the treatment of these pathologies and anti-TNF therapy is now standard of care for RA. Moreover,
these blockbusters currently belong to the top-10 best-selling drugs in the world, with adalimumab
being the world’s best-selling medicine, counting for US $10 billion per year and the total sale of the
various anti-TNF drugs exceeds US $25 billion [245]. Currently, another 151 TNF inhibitors are in the
clinical pipeline.
Three of the five approved TNF-inhibitors are full-length monoclonal antibodies (mAbs):
infliximab (Remicade® and biosimilars Remsima®, Inflectra®, Flixabi®, and Ixifi®), adalimumab
(Humira® and Cyltezo®, Imraldi®, Amgevita®, and Solymbic®) and golimumab (Simponi®). Next to
these, certolizumab (Cimzia®) and etanercept (Enbrel® and biosimilars Erelzi® and Benepali®) are also
approved. Although they all neutralize the TNF activity, they each have different characteristics and
routes of administration. Furthermore, all of them are equally effective against RA, but not against
CD. These discrepancies are attributable to different mechanisms of actions that are not completely
understood [38,250,251] (Table 2 and Figure 3).
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Figure 3. Structure (A); and mechanisms of action (B) of anti-TNF biologics. All anti-TNF biologics 
neutralize membrane-bound (tmTNF) and soluble TNF (sTNF) but, in addition to that, some 
inhibitors also induce outside-to-inside signaling via tmTNF and their Fc-regions mediate antibody-
dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). ADCC: 
antibody-dependent cellular cytotoxicity; CDC: complement-dependent cytotoxicity, Fab: fragment 
antigen binding; IgG: immunoglobulin G; IL: interleukin; NK: natural killer; ROS: reactive oxygen 
species tmTNF: transmembrane TNF. 
4.3. Pitfalls of TNF Inhibitors 
The introduction of TNF-antagonists for treatment of inflammatory disorders substantially 
improved the QoL of the patients, and in IBD it also reduced the number of surgeries and 
hospitalizations. However, the long-lasting use of these drugs coincides with a number of important 
adverse events (Figure 4) [287]. 
4.3.1. High Costs 
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In 1998, inflixima wa the first TNF-targeting antibody approved in the US to treat CD and later
UC. It is a chimeric monoclonal IgG1 Ab that comprises a human constant domain and murine variable
regions. The infliximab biosimilar CT-P13 (Remisma® or Inflectra®) is highly similar to its originator
and therefore clinically used in the same way [252]. Golimumab and adalimumab are full human Abs
that were produced by recombinant DNA technology and certolizumab is a humanized Fab’ fragment
that is conjugated to polyethylene glycol (PEG) to increase the serum half-life. This reduces the
requirement for frequent dosing and possibly reduces the immunogenic nature. Finally, etanercept is a
fusion protein of the extracellular domain of human TNFR2 receptor coupled to the Fc region of human
IgG1. Etanercept binds circulating sTNF and acts as a decoy receptor that prevents TNF-interaction
with the cell surface receptors.
4.2. Mechanisms of Action of TNF Inhibitors
All anti-TNF agents have the same target but not all of them are equally efficacious in all
considered diseases, suggesting that different working mechanisms are inherit to certain antibody
structures. It is clear that particularly in CD alternative effector mechanisms rather than pure TNF
neutralization account for their efficacy whereas this is less the case in RA in which all marketed
anti-TNF drugs are indicated. First, their affinities for TNF are different and generally tmTNF
is neutralized with lower affinity than sTNF [252]. Etanercept is the only one that is capable of
neutralizing lymphotoxin-α (LT-α) and it only neutralizes trimeric TNF. However, TNF inhibitors show
equal sTNF neutralizing potency [276]. Neutralization of sTNF or tmTNF blocks the TNF-mediated
activation of TNFRs and this results in suppression of inflammatory mediators. Indeed, TNF recruits
pro-inflammatory immune cells (cf. Section 3.2) and this process is thus abrogated by the drugs. Use of
the TNF inhibitor also reduces intestinal permeability in CD through decreased intestinal epithelial
cell apoptosis [276].
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Table 2. Anti-TNF biologics that are approved, in the pipeline or discontinued.
Current Approved Anti-TNF Biologics
Drug Biosimilars Structure ApprovedIndication
Administration
Route Ref.
Infliximab CT-P13; SB2 Chimeric mAb
RA, PA, psoriasis,
AS, UC, CD,
pediatric RA & CD
IV, every 8 weeks
following loading at
week 0, 2 and 6
[253–256]
Etanercept GP2015; SB4
Fusion protein:
human
TNFR2:IgG1-Fc
RA, PA, psoriasis,
AS, JIA
SC, every week or
every two weeks [256–258]
Adalimumab ABP501; ZRC3197 Human IgG1 mAb
RA, PA, psoriasis,
AS, JIA, CD,
hidradenitis
suppurativa, uveitis
SC, every two weeks [256,259]
Certolizumab pegol NA
Humanized
PEGylated Fab’
fragment of
humanized iGG1
RA, PA, AS, CD
(only in US and
Switzerland)
SC, every two weeks [260]
Golimumab NA Human IgG1 mAb RA, PA, AS,ulcerative colitis SC, monthly [261]
Anti-TNF Biologics in the Pipeline or Discontinued
Drug Biosimilar Structure Disease Indication Clinical Phase/State Ref.
Infliximab BOW015;PF-06438179 Chimeric mAb RA Phase III/ongoing [256]
Etanercept CHS-0214; HD203
Fusion protein:
human
TNFR2:IgG1-Fc
RA, psoriasis Phase III/ongoing [256]
Adalimumab
BI695501; CHS-1420;
GP-2017; M923; SB5;
ZRC-3197; FKB327
Human IgG1 mAb RA, psoriasis, AS Phase I, II andIII/ongoing [256]
Golimumab ONS-3035 Human IgG1 mAb RA, PsA, AS, UC Preclinical
SSS-07 NA Humanized mAb RA Phase I NCT02460393
AVX-470;
Aveximab-TNF NA
Polyclonal bovine
anti-TNF Ab UC, NEC Phase I
[262,263],
NCT01759056
CDP571 NA
Humanized IgG4
anti-human
TNF mAb
CD PhaseII/discontinued [264]
Ozoralizumab NA Trivalent, bispecificanti-TNF Nanobody
RA, discontinued for
AS, CD and PsA
Phase IIa
(Japan)/ongoing [265]
VHH#1-3 NA Bivalent Nanobody RA Preclinical [266]
Onercept NA
PEGylated dimeric
soluble human
TNFR1
CD, psoriasis, PsA,
RA, sepsis,
endometriosis
Phase II and
III/discontinued [267,268]
Lenercept NA
Fusion protein:
soluble
TNFR1:IgG1-Fc
Severe sepsis, septic
shock, RA and MS
Phase
II/discontinued [53,153]
Hitanercept (T0001) NA TNFR2-Fc fusionprotein RA Phase I (China) [269]
HL036 NA TNFR1 fragment Dry eye disease Phase II NCT03334539
CytoFab NA Polyclonal anti-TNFFab fragment
Severe sepsis, septic
shock
Phase
II/discontinued [270]
Pegsunercept NA PEGylated sTNFR1 RA PhaseII/discontinued [271]
TNF-kinoid NA
Vaccine to induce
anti-TNF Ab,
recombinant human
TNF coupled to
carrier protein KLH
CD, RA Phase II/suspended [272,273]
CYT007-TNFQb NA
Vaccine to induce
anti-TNF Ab,
recombinant TNF
coupled to virus-like
particles of the
bacteriophage Qbeta
Psoriasis Phase I andII/discontinued [274]
TfRMAb-TNFR NA
Fusion protein:
extracellular TNFR2
coupled to mAb
against TfR
PD, AD, ischemic
stroke Preclinical [223,242,275]
(m)Ab: (monoclonal) antibody; AD: Alzheimer’s disease; AS: Ankylosing spondylitis; CD: Crohn’s disease;
Fab: fragment antigen binding; JIA: juvenile idiopathic arthritis; KLH: keyhole limpet hemocyanin; MS: multiple
sclerosis; NEC: necrotizing enterocolitis; PEG: polyethylene glycol; PsA: psoriatic arthritis; PD: Parkinson’s disease;
RA: rheumatoid arthritis; TfR: Transferrin receptor; TNFR: TNF receptor; UC: ulcerative colitis; VHH: variable
domain of heavy-chain only antibodies NA: non-applicable.
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The TNF blockers’ ability to crosslink tmTNF can be different, e.g., infliximab forms more stable
complexes with tmTNF than etanercept. Consequently, binding of infliximab to tmTNF can activate
the “outside-to-inside signaling” or reverse signaling, and, in that case, TNF is considered as a receptor
rather than a ligand (Figure 3). As a direct consequence of this interaction, apoptosis is induced in
the tmTNF-expressing immune cells and this was proposed as one of the mechanisms of action in
CD. This mechanism also impairs their production of pro-inflammatory mediators. Interestingly,
apoptosis can also indirectly be induced in immune cells upon anti-TNF treatment. In CD, there is an
anti-apoptotic signal induced by the interaction between monocytic tmTNF and TNFR2 expressed
by CD4+ T cells. This mechanism is critical for granulomatous inflammation seen in CD, but this
interaction is inhibited by anti-TNF resulting in lamina propria T cell apoptosis [277,278]. As the
affinity for tmTNF is not similar among the different anti-TNF drugs, clinical features against this
type of inflammation are not equal as well. Indeed, etanercept cannot activate reverse signaling
via tmTNF which might explain its inefficiency in CD [13,279]. Thus, these drugs might stimulate
apoptosis by reverse signaling or impairing apoptosis by abrogation of the TNF/TNFR signaling
pathway. Importantly, TNF can also mediate other forms of cell death such as necroptosis [22,122]
(cf. Section 2). Consequently, blockage of TNF might also impair this inflammatory process which
might also account for the efficiency of the drugs. However, to our knowledge, not much research has
been done about this topic.
In addition to their direct TNF-related capacities, the TNF-inhibitors have a panoply of other
effects although currently not all their molecular mechanisms of action are completely understood
[252,276]. Infliximab, adalimumab and golimumab are the only full-length mAbs and thus they also
possess Fc-effector activity in addition to their general TNF-blockage properties. As a result, they can
induce antibody-dependent cellular cytotoxicity (ADCC) and activate the complement pathway
leading to cell-dependent cytotoxicity (CDC) and apoptosis (Figure 3). Etanercept contains a truncated
Fc-domain without the CH1 domain of IgG1, therefore it induces ADCC and CDC but to a lower extent
than the mAbs [252]. Certolizumab pegol, being a Fab’ fragment, is due to its structure incapable of
inducing ADCC and CDC and therefore its working mechanism does not rely on the complement
pathway [280] (Figure 3).
In IBD, also the interplay between the IgG1-Fc domain of the anti-TNF antibodies and the
Fcγ-receptors (FcγR) on macrophages accounts for the efficacy of the anti-TNF antibodies by increasing the
number of regulatory CD206+ macrophages upon activation. This M2-type macrophage subset expresses
specific membrane markers and inhibits T cell proliferation [281]. Alternatively, adalimumab promotes
the interaction between monocytes and Tregs via TNFR2 in RA. Adalimumab enhances the expression of
tmTNF in monocytes upon binding which improves the interaction between tmTNF and TNFR2 on Tregs
and boosts their suppressive activities [282]. In addition, infliximab gives rise to a CD4+CD25hiFoxP3+ Treg
population that restrains pro-inflammatory cytokine production. This newly generated Treg population
compensates for the natural Treg pool that is defective in autoimmune diseases such as RA [283].
The anti-TNF inhibitors were investigated in many observational studies as well as in open-label
extensions of the original double-blind trials and in post-marketing observational studies. These studies
provided data about the long-term efficacy and safety of the drugs. Generally, the anti-TNF inhibitors
were found to be well-tolerated and to improve health-related quality-of-life (QoL) outcomes in the
aforementioned diseases [284]. For RA, anti-TNF drugs are now standard-of-care, initiated after failure
of treatment with the immunomodulator methotrexate (MTX) in patients. In most of the RA cases
(70–80%) TNF-inhibitors are used as combination therapy with MTX. Systematic reviews of clinical
trials demonstrated an additional effect of this combination in RA [245,285], whereas for CD the
results from clinical trials comparing monotherapy with combination therapy were conflicting [286].
It should be noted that the risk for adverse outcomes is possibly increased with combination therapy.
The combination of etanercept with MTX has similar efficacy in the therapy of RA as infliximab and
adalimumab, while it is not active against CD.
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4.3. Pitfalls of TNF Inhibitors
The introduction of TNF-antagonists for treatment of inflammatory disorders substantially
improved the QoL of the patients, and in IBD it also reduced the number of surgeries and
hospitalizations. However, the long-lasting use of these drugs coincides with a number of important
adverse events (Figure 4) [287].
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4.3.1. High Costs
Anti-TNF drugs are real blockbusters for the pharmaceutical companies because this is the
best-selling p arma eutical drug class with sales over US $25 billion. This puts a monumental pressure
on health care sy tems, meaning that many ountries even cannot afford a decent policy around these
dru s. A trospective tudy p rformed in 2016 estimated the a nual cost of the use of biologics per
atients in the USA. The most used biological was etanercept (48%), followed by adalimumab (29%)
and i fliximab (12%) and he annual osts pe treate patient were US $24,859 for etanercept, US
$26,537 for adalimumab and US $26,468 infliximab [288].
4.3.2. Clinical Response
Although many patients benefit from treatment with anti-TNF drugs, a big problem in the
clinic remains the high number of patients that do not respond to the therapy: 13–40% of patients
fail to respond to initial anti-TNF therapy (primary non-responders) and up to 50% of patients
lose responsiveness during therapy (secondary non-responders) [289]. Primary non-response is
defined by the lack of improvement of clinical signs and symptoms with induction therapy. Loss of
clinical remission frequently occurs in CD patients treated with anti-TNF drugs and when the
treatment fails the therapeutic options are often limited [290]. Therefore, early identification of
patients at risk is of major clinical importance. Whether a patient responds well to the initiated
therapy depends on multiple clinical (e.g., disease phenotype and response to previous therapies),
genetic and immuno-pharmacological variables [291]. In IBD patients, mucosal healing is not obtained
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in 50% of the patients treated with anti-TNF biologics, and therapeutic efficacy is shown to be
dependent on the interaction between the Fc region of the anti-TNF IgG and the cellular FcγR. Recently,
a hypo-fucosylated form of adalimumab was designed and was found to have improved mucosal
healing properties thanks to its higher affinity to FcγRIII and induction of CD206+ macrophages [281].
Consequently, some studies correlated the low-affinity FcγRIIIa allotype in IBD patients with lower
changes to respond to therapies with IgG1 Ab infliximab and reduced mucosal healing [292]. Currently,
elaborate studies are ongoing to identify inflammatory biomarkers that allow the stratification of
patients into responders and non-responders. Some biomarkers seem promising, although they still
have to be validated in large patient cohorts to verify their specificity and reliability to predict the
response in the clinic [252,291,293].
Secondary non-responsiveness can be explained by the formation of anti-drug antibodies (ADAs)
(e.g., anti-anti-TNF antibodies) in a subset of patients and the risk of loss-of-response is increased by at
least threefold when ADAs are present [291] (Figure 4). ADAs were not only found against the chimeric
mAb infliximab, but also against the fully humanized mAbs adalimumab and golimumab. This is
possibly a consequence of the interaction between anti-TNF and tmTNF on antigen presenting cells
and the subsequent rapid internalization. The internalized anti-TNF will be processed and its peptides
displayed on the surface of the APCs will mount a T cell proliferation response [294]. Unfortunately,
technical factors, standardization of the assays used to determine ADAs, and the timing of the
measurements makes this a complex subject to investigate. The neutralizing ADAs that inhibit the
functionality of the biologics are only a subset of the ADAs that can be found in patients. Neutralizing
ADAs are generally directed against the biological active site of the drug, e.g., antigen binding part
of the drug. The loss-of-response elicited by neutralizing ADAs can be countered by dose-escalation
or by switching to another anti-TNF drug, but sometimes the therapy needs to be discontinued [295].
A good drug compliance and concomitant treatment with immunosuppressive agents demonstrated a
reduction in the occurrence of ADAs in multiple clinical trials and improved clinical outcomes [276,296].
In addition, co-treatment with MTX was found to be beneficial in that regard [286]. ADAs may form
immune complexes that are rapidly cleared by the reticulo-endothelial system and are associated
with decreased drug levels, short duration of response and higher risk of infusion reactions and even
acute hypersensitivity (anaphylaxis) [297,298]. Luckily, the impact of the ADA is inversely correlated
with their frequency of occurrence, meaning that binding ADAs are generally more common than
neutralizing ADAs or ADAs that form immune complexes. Surprisingly, the presence of ADAs may be
permanent but may also be transient, appearing in one single measurement without recurrence [299].
To reduce the risk of loss-of-response, therapeutic drug monitoring (TDM) has become standard
of care in the clinical setting for many clinicians, because there is a well-established correlation between
serum trough levels of the drugs and clinical response [291]. Indeed, adaption of the dose based on the
trough levels were more effective at inducing remission in IBD patients than clinic-based dosing [300].
TDM allows increasing the dose in patients with sub-optimal drug levels and this leads to better clinical
effects. Moreover, it is widely believed that sub-therapeutic doses contribute to the development
of ADAs, further highlighting the importance of TDM. Dose de-escalation is done in patients with
supra-optimal levels, leading to lower drug exposure and reduced costs without impact on the clinical
response [301,302].
4.3.3. Increased Susceptibility to Infection and Malignancies
The beneficial effects of anti-TNF medication are undeniable but there are serious concerns
considering their safety. In addition to acute problems, such as infusion reactions, other severe adverse
events might occur (Figure 4). Because TNF has an important function in host defense and in the
protection against (intracellular) bacteria, as discussed in Section 3.2, infectious complications due
to shutdown of this arm of the immune system are a big concern in patients treated with anti-TNF
drugs. Post-marketing data have revealed a rate of 0.69% serious infections and also a drastic increase
of activated tuberculosis with aberrant granuloma formation was reported [303,304]. These unwanted
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effects are considered as a class effect, because all anti-TNF drugs appear to have an equally high
risk in acquiring new tuberculosis infections, although the mAbs seem to cause more infections
with reactive latent tuberculosis [304]. This serious health issue initiated the recommendation to
screen for tuberculosis with the QuantiFERON Gold Test and to treat infections, even when they
are latent, before initiating the anti-TNF treatment [305]. Since then, the number of reports on
tuberculosis infections has decreased, but other untypical opportunistic viral and fungal infections have
popped up, including cytomegolavirus infection, Pneumocystis jirovecii pneumonia, histoplasmosis
and aspergillosis. Risk factors to develop these infections are age and concomitant treatment with
corticosteroids, and the overall risk of these infections should be considered before the treatment is
started [306].
Regarding the risk for malignancies, studies in mice attributed an important role to TNF in the
process of tumor immune surveillance [307]. However, TNF KO mice do not spontaneously develop
tumors, not even in a susceptible background [38]. Notwithstanding this observation, serious concerns
about anti-TNF drugs in human patients remained. Earlier studies reported an increased risk for
lymphomas (Hodgkin’s lymphoma, B cell lymphoma, etc.) and other malignancies, but more recent
studies and registry databases found no association between anti-TNF treatment and the occurrence of
solid or hematologic cancers [308]. However, it is possible that significances are unclear because the
studies are underpowered due to the low incidence of these adverse effects. In addition, because the
relatively short period of clinical use of the anti-TNF drugs and the long time it may take for tumors to
develop, it may be too early to make good and relevant association and risk studies. Anyway, in the
case cancer is found during anti-TNF treatment, it is advisable to interrupt the treatment until the
cancer is under control [309]. Noteworthy to conclude, patients that use anti-TNF medication for
chronic inflammatory disease are already at higher risk for infections and malignancies for several
disease-related reasons, regardless of their treatment [308,310].
4.3.4. Demyelinating Disease and Other Neurological Side Effects
Neurological side effects have been reported and recent data suggest a role for anti-TNF drugs
in the induction of neurological disease, especially demyelination of the CNS as well as implications
at the level of the peripheral nervous system (Figure 4). The prevalence of these side effects has
been estimated to range between 0.05% and 0.2% for infliximab, etanercept and adalimumab [311].
Eighty percent of the reports about CNS demyelination are about optic neuritis, but also cases of
MS or MS-like diseases have been reported. In addition, peripheral nervous system disorders were
documented, such as Miller Fisher syndrome, Guillain-Barré syndrome and other neuropathies [312].
There are several hypotheses to explain the possible relationship between TNF-antagonists and
demyelination but none of them is believed to be adequate [313]: (1) The occurrence of demyelinating
disease could be attributed to the unmasking of a latent pre-existing form of MS, to the emergence of a
new demyelination episode or to incidental coexistence of the two disorders. (2) The administration
of anti-TNF agents could unmask a latent infection that is critical for the development of MS [311].
(3) Local TNF production in the CNS by pathogenic T cells induces demyelination and, therefore,
the demyelination seen with TNF-antagonists may look paradoxical. However, the presence of
CNS barriers, e.g., the blood–CSF and BBB, renders CNS access almost impossible as the biologics
have a size of approximately 150 kDa. Even though the permeability of the barriers is increased in
inflammatory conditions, this does not lead to significant blood-derived protein increment, and by
inference anti-TNF biologics, in the CSF [313]. In patients, infliximab was not detected in the CSF,
even in presence of active MS and BBB impairment [152]. (4) Prolonged blockage of peripheral
TNF increases the T cell response to a specific antigen. This may lead to a significantly increased
amount of highly activated myelin-specific autoreactive T cells, ultimately exacerbating autoimmune
demyelinating diseases [313]. (5) Anti-TNF drugs can neutralize TNF systemically but not within the
CNS. This results in an overall reduction in TNF in the body but relatively unchanged TNF levels in
the brain. This creates an artificially high local concentration of brain (the “sponge” effect) leading to
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local tissue injury. Either way, once unexplained neurologic symptoms appear, the anti-TNF treatment
should be discontinued [312,313].
In addition to these neurological disorders, CD patients treated with anti-TNF drugs reported
fatigue which was significantly associated with the use of these drugs. Subgroup analyses also
indicated that long-term therapy duration and combination without azathioprine were risk factors for
the occurrence of fatigue [314,315].
4.3.5. Paradoxical Side Effects
In addition to the “common” adverse effects, there are also paradoxical side effects described in
patients treated with anti-TNF drugs (Figure 4). They represent the unexpected onset or exacerbation
of an autoimmune disease for which TNF blockers are indicated other than the one the patient is
treated for. These disorders are mainly reported in patients with rheumatic diseases and IBD [316].
Psoriasiform skin reactions are the most frequently observed dermatological adverse effects seen in
patients treated with anti-TNF therapy, but also uveitis, vasculitis, Graves’ disease and granulomatous
diseases such as sarcoidosis have been reported [316–320]. Psoriatic skin reactions mostly occur about
five months after first exposure to TNF blockers. Large cohorts also reported that RA patients treated
with etanercept for juvenile idiopathic arthritis, AS or RE developed new-onset CD. Another common
paradoxical side effect is the appearance of autoantibodies and a subset of patients developed
drug-induced lupus erythematosus (DILE) [321]. SLE is a heterogeneous disease characterized by
the production of autoantibodies that form immune complexes leading to inflammation in various
organs. TNF is involved in the pathology of SLE but an open-label study showed that TNF inhibition
by itself led to the paradoxical formation of autoantibodies [322]. Unfortunately, these adverse effects
are probably underreported and the mechanisms unclear. There are indications that an imbalance of
cytokines towards IFNs, chemokines and probably IL-17 is implicated in the pathogenesis [323,324].
The first hypothesis attributes a central role to type I IFN-α, which is highly implicated in psoriasis [320].
TNF downregulates the production of IFNs by the plasmacytoid DCs, thus TNF inhibition would
enhance IFN production thereby favoring psoriasis development [320]. In addition, an imbalance in
cytokines of the IL-12/IL-23 pathway via activation of the Th17 pathway is proposed as a possible
mechanism [325]. A third hypothesis accounts for the impairment of the TNF-induced apoptosis of
autoreactive T cells by the anti-TNF drugs. This lack of autoreactive T cell destruction induces new
or aggravated forms of autoimmunity. In these cases, boosting or restoring TNF activity might be
therapeutic [326]. These paradoxical side effects appeared between one month and one year after
initiation of the therapy. When these symptoms appear in patients, withdrawal of the treatment
reverses this unwanted effect in nearly 75% of the cases [316]. As this side effect is considered as a
class effect that is seen with all TNF inhibitors, switching to another inhibitor is mostly not helpful.
5. Other Anti-TNF and TNF-Modulating Drugs
5.1. TNF Inhibitors
In addition to the well-known approved anti-TNF inhibitors, there are several other anti-TNF
drugs developed or under development (Table 2). In China, a phase I clinical trial is completed
with a humanized anti-TNF mAb SSS-07 against RA, but no results are provided yet (NCT02460393).
The bovine polyclonal milk-derived anti-TNF Ab AVX-470 can be administered orally thanks to the
stability of bovine Igs in human intestinal secretions. After oral administration, this Ab remained
localized in the gut, and in a double-blind, placebo controlled study AVX-470 appeared to be safe and
well tolerated, and was associated with dose-dependent increases in clinical and endoscopic remission
in patients with active UC (NCT01759056) [262,263]. The involved company Avaxia Biologics has
created orally administered anti-TNF mAbs, Avaximabs®, that are stable in the gastro-intestinal tract.
These will be explored for the treatment of necrotizing enterocolitis (NEC). Unfortunately, clinical drug
development goes along with many failures too: CDP571 (Humicade®), a humanized mAb against
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TNF failed to demonstrate clinical efficacy for sparing steroids in CD patients and further development
was discontinued [264]. Other approaches than Abs are also considered, as illustrated with the clinical
success of the Nanobodies (Nbs) [327]. A highly promising Nb is generated by Ablynx against TNF
and is called ozoralizumab [328]. This drug is now under clinical investigation to treat autoimmune
diseases and proof-of-concept was already obtained in a phase II RA study [265]. Another bivalent
Nb was also engineered consisting of two monomeric variable domains of heavy-chain only Abs
(VHHs). The construct VHH#1-3 antagonizes the binding of TNF to its receptors with picomolar
potencies. As this drug has a different mode of binding, i.e., it can bind a single trimeric TNF and
blocks two of the three receptor binding sites of TNF, it distinguishes itself from other TNF neutralizing
drugs [266]. The ease of cloning and production allows Nbs to be locally secreted by the genetically
modified probiotic Lactococcus lactis after oral administration, as was done with an anti-TNF Nb [329].
Preclinically, this innovative approach was efficacious in colitis without causing immunogenicity
and is under clinical investigation. In addition, variable new antigen receptor (VNAR) domains
against TNF were developed, originated from immunized sharks. Multivalent VNARs neutralize TNF
at picomolar concentrations and were as efficacious as adalimumab in in vitro models of intestinal
epithelial barrier dysfunction. Therefore, these drugs could be considered as a novel alternative class
of biological agents [330]. Similar to etanercept, Lenercept is a soluble fusion protein consisting of
TNFR1 fused to the hinge region of the IgG1 Fc region. It entered clinical trials for indications such
as sepsis, RA and MS. However, the clinical trial for treatment of RRMS had to be terminated due to
unforeseen exacerbations of the symptoms [53,153]. Hitanercept is a variant of etanercept that carries a
mutation in the TNFR2 domain of the fusion protein and exhibits higher affinity to sTNF and tmTNF
than etanercept [269,331]. In the CIA model for RA, hitanercept is more efficacious compared to
etanercept. Interestingly, hitanercept is also more potent to induce reverse signaling via tmTNF and to
mediate CDC and ADCC. Therefore, the drug also has therapeutic potential in CD and UC. Currently,
the tolerance, pharmacokinetics and preliminary efficacy of hitanercept in RA are assessed in a phase I
clinical trial in China (NCT02481180) [269]. HL036 is a small TNFR1 fragment (19 kDa) with enhanced
ocular tissue penetration. This drug is formulated as an ophthalmic solution and is currently under
clinical investigation (phase II) for dry eyes disease (NCT03334539) after it was shown to be safe in
healthy volunteers. In addition, other formulations for inflammatory ocular diseases are currently
considered. Onercept is a PEGylated form of soluble human TNFR1 that was tested in psoriasis and
CD. Despite promising early clinical results, onercept proved not to have an exceptional efficacy
and safety profile in both diseases and therefore further development was stopped [267,268,332,333].
Another potentially interesting candidate that is based on the same rationale as onercept is pegsunercept,
a PEGylated soluble TNFR1. It has been tested for RA, but also here, development was discontinued
and this decision was based on recommendations of two separate independent Data and Safety
Monitoring Boards [271]. Likewise, the development of the polyclonal anti-TNF Fab fragment
Azd9773 (CytoFab®) was suspended as the drug failed to show efficacy in severe sepsis and septic
shock [270]. Another new therapeutic approach relies on the active immunization with TNF-kinoid or
with CYT007-TNFQb, inducing endogenous polyclonal anti-TNF antibodies that neutralize circulating
TNF in inflammatory immune-mediated diseases. With TNF-kinoid, proof-of-concept was obtained
in a mouse RA model and these findings were translated into the clinic in patients that experience
secondary non-responsiveness of TNF-antagonists. A phase Ia clinical trial showed that therapeutic
vaccination induced dose- and schedule-dependent anti-TNF Abs in RA patients and was well tolerated.
Moreover, patients with anti-TNF Abs showed a trend towards clinical improvement [272]. The drug
was also investigated to treat CD patients, and a high clinical response was reported with remission
rates in half of the patients. However, the clinical efficacy needs to be weighed against the potential
harmful consequences of life-long ablation of TNF and probably for that reason further development
was suspended [273]. The same holds true for CYT007-TNFQb of which the phase I/II clinical trial
was discontinued in psoriasis patients [274]. Progranulin is an endogenous glycoprotein expressed in
neurons and glia cells that directly interacts with TNFR1 and TNFR2. Proganulin has anti-inflammatory
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activities by the inhibition of the TNF activity, and Atsttrin is a progranulin-derived engineered protein
that showed efficacy against RA and osteoarthritis in preclinical models [334,335]. Up until now,
no clinical trials are reported, but also this candidate may be an interesting alternative to the generally
used anti-TNF biologics. The small chemical triazoloquinoxaline inhibitor R-7050 is a TNFR complex
inhibitor that improves the outcome upon intracerebral hemorrhage, suggesting its use as adjunct
therapy in the treatment of neurological injury [336]. The drug does not interfere with TNF-TNFR1
binding, but acts via the inhibition of receptor-adaptor molecules complex formation and subsequent
receptor internalization [336]. In addition, interesting is the approach exploited by the group of
Pardridge. They engineered a BBB-penetrating TNF inhibitor by fusion of the extracellular domain of
TNFR2 to a chimeric monoclonal antibody against the mouse TfR. This Trojan horse approach led to
rapid therapeutically relevant amounts of drug in the brain following intravenous, subcutaneous and ip
administration, and was protective in mouse models of PD, AD and ischemic stroke [223,242,275,337].
Finally, a novel chemically synthesized anti-TNF compound is described. C87 is an TNF-TNFR
interaction modulator as it directly binds to TNF and prevents TNFR signaling and subsequent Casp-8
and NF-κB activation. It was found from an initial screen of ~90,000 compounds and has in vivo
potency. The only remaining challenge is to determine toxicity and stability with longer-term use [338].
5.2. TNF Modulators
Other less specific anti-TNF agents are thalidomide and its derivatives lenalidomide and
pomalidomide, curcumin and minocycline. Initially, thalidomide was indicated as an effective
tranquilizer and painkiller associated with enormous teratogenic side effects in human. Thalidomide is
now recently re-introduced as well-known (non-specific) TNF-inhibitor as it reduces the rate of TNF
synthesis by enhancing the degradation of the transcript. Currently, thalidomide is under investigation to
treat neurodegenerative disorders that implicate TNF-signaling such as AD, PD and amyotrophic lateral
sclerosis (ALS) as this small-drug molecule can penetrate into the brain [235,339–342]. The broad-spectrum
tetracycline antibiotic drug minocycline decreases TNF synthesis in addition to its bacteriostatic and
anti-inflammatory actions. Additionally, it also inhibits MMPs, reduces cyclooxygenase 2 (COX-2) activity
and prostaglandin E2 production, and attenuates apoptosis [12]. In PD models, minocycline attenuated
MPTP-induced microglia activation, but could not abolish the neurotoxicity [237]. By contrast,
curcumin (diferuloymethane) is a natural anti-inflammatory agent that inhibits TNF transcription
at several levels, but mostly via inhibition of NF-κB. Consequently, curcumin also antagonizes other
pro-inflammatory cytokines including IL-1β and IL-6. It is a broad-acting anti-TNF that can be
orally consumed via natural food spices. Unfortunately, it is poorly soluble in water and has a
poor bio-availability [343]. Currently, neuroprotective characteristics are attributed to curcumin and
therefore it is under active investigation for AD amongst others [344]. In addition, xanthine derivate
pentoxifylline and bupropion have shown to decrease TNF synthesis [345]. By increasing the
signaling at beta-adrenoreceptors and D1 receptors, bupropion increases cyclic AMP (cAMP) which
subsequently inhibits TNF synthesis [346]. Unexpectedly, a novel crosstalk pathway between neural
and immune receptors was found as several 5-hydroxytryptamine (HT) agonist hallucinogens (such
as (R)-DOI, TCB-2, LSD and LA-SS-Az) are potent TNF inhibitors, with DOI being the most potent
one. This indicates that activation of the serotonin 5-HT(2A) receptors represents a novel potential
therapeutic avenue for TNF-involving disorders [347,348].
6. A New Chapter of Inventive TNF Manipulating Approaches
The anti-TNF drugs on the market were based on the wide perception that TNF is a pathological
factor, ignoring the fact that TNF can also have beneficial and unique indispensable properties e.g.,
in immune regulation and tissue regeneration, as discussed above [33,93,102,114,349,350]. This is also
illustrated by the numerous side-effects that are inherent to long-lasting TNF blockage. Therefore,
more discriminative approaches hold the potential to increase the safety and efficacy of the drugs.
Indeed, as outlined in previous sections, especially for neurological diseases more selective approaches
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are warranted as there is a clear discrepancy between TNFR1 and TNFR2 signaling in the brain
typified by the aggravated disease symptoms that are induced by anti-TNF drugs in MS patients.
Nonetheless, also non-neurological diseases will benefit from receptor-discriminatory drugs as
pan-TNF neutralization induces neurological phenomena in some patients.
6.1. Selective TNFR1 Targeting
Given that TNFR1 and TNFR2 mediate different cellular effects, it is interesting to selectively
target one of the two. This field is currently actively explored via several approaches [97]. ATROSAB is
a human TNFR1-specific antibody that demonstrated to efficiently block the activity of TNF and
LT-α in vitro [351,352]. Williams et al. described a monoclonal hamster IgG against mouse TNFR1
that was effective to reduce symptoms in EAE [170], and also a TNFR1 selective antagonistic mutant
TNF protein, PEG-R1ant-TNF has been described to have this property [169]. PEG-R1ant-TNF was
also effective in the CIA model for RA and against arterial inflammation [353,354]. The efficacy of
a single TNFR1-binding domain bispecific antibody, MDS5541, was evaluated against RA in vitro
in synovial membrane cell cultures from RA patients and in vivo in the CIA model of RA [107,355].
Selective TNFR1 inhibition established with this drug led to the expansion and activation of Tregs with
upregulation of FoxP3-dependent genes. This effect again highlights the importance of preserving
the TNF/TNFR2-mediated signaling pathway. In addition, two fully human anti-TNFR1 single
domain antibodies have been developed and were investigated by GlaxoSmithKline [356]. The first,
GSK1995057 attenuated lung injury in different preclinical models of acute respiratory distress
syndrome [356,357]. However, in a phase I clinical trial with this small inhibitor, infusion reactions
arose in healthy volunteers because of the presence of naturally occurring pre-existing ADAs [358,359].
Consequently, a new trial was initiated in which only healthy subjects prospectively demonstrated
to be seronegative for the pre-existing ADAs were eligible for participation (TFR116343). In these
subjects, nebulized GSK1995057 prevented acute lung injury in an LPS-induced model. The drug will
now be evaluated in a phase IIa clinical trial [360]. To deal with the problem of pre-existing ADAs,
a second single domain was designed (GSK2862277). In a phase I trial, this drug was well tolerated
by both the inhaled and iv route [359]. A placebo-controlled randomized phase II trial was set up
in patients that undergo oesophagectomy surgery and that were at risk to develop acute respiratory
distress syndrome. The drug GSK2862277 was administered as an orally inhaled aerosol pre-operative,
but the trial was terminated earlier as the study met the designed stopping criteria (NCT02221037).
However, GSK still concludes that selective antagonisms of TNFR1 using inhaled drugs might offer
therapeutic benefit in patients with acute respiratory distress syndrome. Another interesting approach
to selectively target TNFR1 is by interfering with the PLAD association, necessary for TNF/TNFR1
signaling [16]. Targeting the TNFR1 PLAD domain has already been proposed by several groups
as a promising strategy in autoimmune diseases such as diabetes and RA [361,362]. The marketed
anti-asthma drug zafirlukast also disrupts the interaction between the TNFR1 PLAD domain and is
thus considered as a selective TNFR inhibitor [363].
Importantly, our research group also generated a trivalent human TNFR1 inhibiting Nanobody
consisting of two paratopic TNFR1 binding Nbs linked to an anti-albumin Nb. This Nb only binds
to human TNFR1 without being cross reactive for the mouse homologue. One of these Nbs also
competitively inhibited the TNF/TNFR1 signaling, but the potency of this Nb was improved after
incorporation in the TROS construct. This construct effectively inhibited TNFR1 signaling in vitro
and ex vivo on isolated colon biopsies from CD patients [328]. Proof-of-concept of this promising
molecule has been first delivered in humanized mice carrying a human TNFRSF1A gene, subjected to
the mouse EAE model of MS. In these transgenic mice Prophylactic as well as therapeutic ip
administration of the drug prevented or halted disease development, respectively [171]. The drug
prevented demyelination and treatment with TROS maintained the expression of several important
neuroprotective genes that are downregulated in MS patients. Because choroid plexus TNFR1 is also
an important detrimental mediator in AD as was recently shown by the group, also the possibility to
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inhibit TNFR1 therapeutically with TROS was investigated in the acute AD model of icv oligomerized
amyloid beta (AβO) injection. Strikingly, TROS prevented the AβO-induced memory decline in these
mice after icv injection, confirming the therapeutic possibilities of this molecule [186].
6.2. Selective TNFR2 Targeting
The opposite approach that is currently investigated implies TNFR2 activation to stimulate
the TNFR2-mediated protective pathways in autoimmunity and neurodegenerative diseases [364].
It has been suggested that this strategy might be superior to TNFR1 antagonism because of the
restricted cellular expression of TNFR2. TNFR2 is not only considered as a costimulatory receptor for
T cells and critically involved in the development of Tregs, recent studies also provide new insights
into the role of tmTNF/TNFR2 signaling in the suppressive activity of myeloid-derived suppressor
cells (MDSCs). Indeed, MDSCs require membrane TNFR2 expression to exert optimal suppressive
activity [365,366]. Interestingly, chronic inflammation increases the sensitivity of these suppressive
cells for TNFR2 costimulation [367]. Efficient TNFR2 activation requires oligomerization of TNFR2
by tmTNF. Alternatively, oligomerized soluble forms of tmTNF should mimic receptor activation via
tmTNF [168,368]. Several TNFR2 agonists have already been developed such as the TNFR2-specific
variant of mouse TNF that is trimerized using the trimerization domain of chicken tenascin C as
has been done in TNCscTNF80. This drug protected against graft-versus-host disease (GVHD)
via host Treg expansion [369]. Lamontain and colleagues recently confirmed that stimulation with
TNCscTNF80 effectively leads to expansion of Tregs and ameliorates established CIA in mice [370].
Another TNFR2-selective TNF mutein EHD2-scTNFR2 consists of a covalently stabilized human
TNFR2-selective single-chain TNF fused to the dimerization domain EHD2 derived from the heavy
chain domain of IgEs [174]. TNFR2 agonists could rescue human neurons from death induced
by oxidative stress or stimulate Tregs in type I diabetes. These could be useful in patients with
TNF-mediated neurodegeneration or as a correctional therapy in diabetes patients [371]. Additionally,
TNFR2 is expressed by all diseased CD8+ T cells and TNFR2 agonism has been shown to selectively kill
insulin-autoreactive CD8+ T cells in blood of diabetic patients by an altered signaling pathway [184].
This approach is very attractive and is preclinically assessed for type I diabetes and other autoimmune
diseases. However, despite the promising features of TNFR2 agonism, it can also be a risky approach as
it might enhance the accumulation of pathogenic T cells [372]. In type I diabetes, it has been suggested
that tmTNF signaling via TNFR2 is responsible for islet destruction, arguing for TNFR2 antagonism
instead [373]. Interestingly, Dong et al. combined TNFR1 antagonism and TNFR2 agonism in a model
of N-methyl-D-aspartate (NMDA)-induced acute neurodegeneration. Administration of ATROSAB or
of a TNFR2-selective TNF mutant EHD2-scTNFRR2 reverted neurodegeneration-associated memory
impairment and protected cholinergic neurons against cell death [174]. In addition of the use of
TNFR2-agonizing TNF muteins, one may also consider co-administration of the cholesterol lowering
drug lovastatin. Indeed, in further support of the importance to preserve TNFR2 signaling in AD,
it was shown that statins reduced progression of AD in clinical trials or even prevented the onset of
it [374,375], and lovastatin established this by increasing TNFR2 expression. Additionally, the drug
protected primary cortical neurons against glutamate-induced excitotoxicity [376].
In contrast to TNFR2 agonism, TNFR2 inhibition was proposed as an effective anti-cancer strategy as
TNFR2 has been identified as a human cancer oncogene. Indeed, many cancer cells are characterized by
TNFR2 expression that promotes the expansion of tumor cells [14]. Recently, TNFR2 has also been found
on the surface of a highly immuno-suppressive tumor-infiltrating subset of Tregs [109], and therapies that
target and eliminate Tregs are currently investigated as cancer treatment [377]. TNFR2 antagonism could
therefore act as a double-edged sword as the group of Faustman elegantly showed. TNFR2 antibodies
directly blocked the tumor growth, inhibited Treg proliferation and enabled T effector cell expansion
which could help amplify effective anti-tumor immune responses [15]. Furthermore, the combination
of TNFR2 antagonists with immunotherapeutic stimulants synergistically improves the therapeutic
efficacy in colon cancer mouse models [378].
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6.3. TNF-Inducing Vaccines
Interestingly, also vaccines that stimulate endogenous TNF release are currently evaluated as
a long-term modulating immuno-intervention in clinical trials in type 1 diabetes and have been
investigated in MS (NCT02081326; NCT00607230; NCT00202410) [349,379]. These approaches are less
toxic than recombinant TNF treatment, and can be established via immunization with the Bacillus
Calmette-Guérin (BCG) vaccine. This live tuberculosis vaccine contains Mycobacterium bovis, known to
stimulate the innate immune system by inducing the host to produce TNF that subsequently kills
the autoreactive T cells. BCG vaccination of longstanding type I diabetic subjects led to more death
insulin-autoreactive T cells and transiently induced beneficial Tregs for 4–6 weeks after vaccination [379].
This vaccine is now evaluated in a phase II trial with a duration of five years to establish the long
term consequences [349]. In addition, in MS, the clinical benefit was shown, consistent with the
outcome in diabetic patients [380]. Vaccinated RRMS patients had a reduction in disease activity and
the progression of brain lesions was prevented. The effects of BCG vaccination were also assessed in
subjects with clinically isolated syndromes, and at the end of the five-year trial, 58% of the subjects did
not progress into MS whereas this was only 30% of the placebo-treated group, and no adverse events
were reported [381].
6.4. Selective Targeting of sTNF
Instead of targeting the receptors, approaches that selectively target sTNF have also been
proposed. One of the most promising drugs is the dominant negative peptide Xpro1595 [382,383].
Xpro1595 selectively binds to soluble TNF monomers without interfering with tmTNF and forms inactive
heterotrimers that are unable to interact with the TNFR [382]. Interestingly, XPro1595 suppressed
inflammation in both the CIA and the mouse collagen antibody-induced arthritis (CAIA) model for RA
without compromising the innate immunity to L. monocytogenes infection [382]. The efficacy of XPro1595
has also been tested in other preclinical models. Indeed, in two mouse MS model, EAE and the
cuprizone model, subcutaneous injection of XPro1595 was therapeutic and promoted axon preservation
and remyelination [164,165,167] and in AD 5xFAD mice it decreased Aβ plaque load and rescued
impaired long-term potentiation [189]. Locomotor functioning was improved after spinal cord injury,
but only after central administration [163] and intraocular administration of XPro1595 promoted retinal
ganglion cell survival in a rat model of ocular hypertension glaucoma [384]. Icv infusion of XPro1595
also prevented the development of depressive-like symptoms induced by exposure to artificial light at
night [385]. Peripheral administration of XENP345, a PEGylated variant of XPro1595, in the 6-OHDA
model for PD attenuated nigral and dopaminergic cell loss [196,198] (cf. Section 3.4.4). Finally, in the
established mouse model of Huntington’s disease (R6/2 mice), particularly icv injection of XPro1595
improved the functional outcome of these mice [386]. Vaccination with virus-like particles of the
bacteriophage Qbeta that was covalently linked to sTNF led to Abs specifically neutralizing sTNF.
These endogenously raised Abs protected mice from inflammation in RA mouse models [274].
6.5. Cell-Type Restricted TNF(R) Targeting
Cell-type restricted targeting of TNF is a new innovative approach that has been suggested by
the group of Nedospasov [387]. TNF signaling represents a complex network, and the deleterious
or beneficial outcome of TNF depends not only on the receptor via which it signals, but also
on the physiological circumstances and the cell type. Indeed, cell-type specific conditional TNF
knockout mice point to differential roles for myeloid and T cell-derived TNF in host defense and in
several inflammatory mouse models (Table 3). For the immune response against L. monocytogenes,
both myeloid and T cell-derived TNF have a similar contribution depending on the bacterial
load [387]. The situation in different during M. tuberculosis infection in which T cell-derived TNF
is needed to control the infection and can better not be blocked, whereas myeloid cell-derived TNF
is dispensable [40]. For the formation of GCs, another source of TNF, namely B cells, is important.
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However, to maintain the formation of the GCs and FDC networks in lymph nodes, B cell-TNF
synergizes with T cell-TNF [388]. In disease settings, TNF derived from myeloid cells was generally
found to have detrimental functions in LPS/D-galactosamine induced hepatotoxicity, in experimental
arthritis and in EAE [147]. Conditional ablation of macrophage TNF led to protection against
diabetic nephropathy in streptozotocin-induced diabetes [389]. Conversely, T cell-derived TNF
demonstrated nonredundant protective roles in these diseases, although in EAE also pathogenic effects
of T cell-derived TNF are described [147]. Interestingly, intestinal inflammation could be induced by
chronic TNF expression by the IECs whereas in the T cell transfer model of murine colitis, TNF from
non-T cells seems to be responsible for colitis induction [390]. Intestinal pathology in TNF∆ARE mice
is induced by TNF derived from innate (myeloid cells) and adaptive (CD8+ T cells) effector cells as
well as IECs via interacting with TNFR1 on mesenchymal cells [85,391,392]. These examples led to the
idea of selective inhibition of TNF produced by myeloid cells thereby sparing the protective effects of
TNF that is produced by other cells such as T cells [393]. To establish site-directed TNF neutralization
myeloid cell-specific TNF inhibitors (MYSTIs) were designed that locally enrich at the cell membrane.
These VHH-based bispecifics consist of one arm that binds TNF and another arm directed against the
myeloid surface markers F4/80 or CD11b. These drugs retain endogenously generated TNF in vitro,
and in vivo the F4/80-directed MYSTI protects against LPS/D-Gal lethal toxicity and was also active
in the anti-collagen antibody transfer arthritis model [394,395]. Additionally, treatment with these
drugs led to beneficial outcomes in an in vivo model of acute hepatotoxicity as macrophage-derived
TNF is directly captured at the source of production [394,396].
Interestingly, in the TNF-induced shock model IEC-restricted TNFR1 expression is sufficient
to induce IEC-apoptosis, but chronic targeting of IECs by endogenous TNF is not enough to
induce IBD pathology indicating that TNFR1 expressed on other cell types is required for effective
pathology [68,69,397]. This means that selective IEC targeting of TNFR1 is not interesting to consider as
IBD therapy. In TNF∆ARE mice, the RA pathology is independent of TNF-mediated adaptive immune
responses (T and B cells), but it is mediated by TNFR1 on joint (synovial) fibroblasts [85,391,398].
In addition, astrocyte-specific TNFR1 blockage might be considered to prevent memory deficits in
MS [172] or CD8 T cell-TNFR2 antagonism for induction of apoptosis in autoreactive lymphocytes in
diabetes [184].
Instead of targeted TNF neutralization, there are also several indications that might benefit from
targeted TNF supply, for example to exploit its anti-cancer properties. Unfortunately, TNF’s intrinsic
and unacceptable toxicity hampers its use as immunotherapeutic. This obstacle can be circumvented by
the creation of Activity-on-Target cytokines (AcTakines). These immunocytokines consist of mutated
cytokines with reduced binding affinity coupled to a targeting moiety that guides the cytokine to the
desired cell target. The activity of the mutated cytokine is only restored after local enrichment at the
targeted cell types. This strategy will greatly reduce the off-target adverse effects and improve the
desired efficacy [399].
6.6. Multispecific Approaches
Simultaneous blockage of multiple pathways might directly cope possible compensation
mechanisms that neutralize the initial effect of the drug. Alternatively, this approach can also directly
increase the potency of drugs. In the pathogenesis of psoriasis, a prominent role for TNF has been
described and this is illustrated by the success of the TNF inhibitors in this disease. In addition to
TNF, recent data also suggest an important role for type I IFN in psoriasis. Interestingly, blockage of
TNFR1 or the IFN receptor 1 (IFNAR1) only partially protects mice against imiquimod-induced
psoriasis, whereas double KO mice lacking both receptors showed superior protection in this model.
This was explained by the presence of a sustained type I IFN production in TNFR1 single KO
mice [324]. As there is also a clear synergy between TNF and IL17A or IL17F, bispecific antibodies
that bind both TNF and IL-17 were designed with the intend to be superior for the treatment of
RA, PsA and AS, and to overcome limited therapeutic responses obtained with single cytokine
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neutralization [401]. Two different bispecific biologics (e.g., COVA322 and ABT-122) are currently
under clinical investigation, but the clinical development of COVA322 was terminated due to safety
issues (NCT022437870). ABT-122 is a dual-variable domain IgG under clinical development by
AbbVie and seems promising after evaluation in several phase I and II trials in healthy volunteers
and in subjects with RA and PsA [402,403]. Similar approaches were inquired with the TNF/IL-6
and TNF/IL-23 neutralizing Abs that were patented [404,405]. The first approach could ameliorate
the clinical progress in CIA more than the single treatments did [406]. Additionally, RA patients
were treated with the combination of IL1 and TNF neutralizing drugs but this therapy did not have
added value [407], although it seemed promising in preclinical sepsis models and in acute myeloid
leukemia [79,408]. However, the complete blockage of host defense mechanisms should be kept in mind
as a plausible destructive side effect. In the context of sepsis, our group developed a bispecific Nb that
targets MMP8 and TNFR1, as discussed in Section 3.2.2. In addition to these double cytokine-hitters,
the combination between anti-TNF with anti-angiogenic agents were studied in the context of RA.
The bispecific Zybody that was generated by the genetic fusion of Ang2-targeting peptides to the
heavy chain of an anti-TNF Ab showed superior efficacy compared to the single hit strategy [409].
Table 3. Distinct functions of TNF produced by T cells and myeloid cells in several experimental
mouse diseases.
Disease Model
Cellular Source of TNF
Ref.
Myeloid Cells T Cells
T cell transfer colitis model Pathogenic Non-redundant [390]
TNF∆ARE intestinal inflammation Pathogenic Pathogenic [392]
TNF∆ARE joint inflammation NA Non-redundant [85]
L. monocytogenes infection Protective Protective [400]
M. tuberculosis infection Dispensable 1 Protective [40]
Systemic LPS/D-Gal hepatotoxicity Pathogenic Dispensable [40]
Autoimmune arthritis Pathogenic Protective [393]
EAE
Pathogenic during early phase Protective and
pathogenic [147]protective in late phase
ConA-hepatitis Pathogenic Pathogenic [40]
Diabetic nephropathy Pathogenic ND [389]
1 Mediates immune functions of cells at early stages of infections, but dispensable for protection. ConA: Concanavalin-A;
EAE: Experimental autoimmune encephalomyelitis; ND: Not determined.
The establishment of a bispecific therapeutic also allows targeting of cytokine-neutralization
on cytokine-producing cells (cf. Section 6.5) or at particular anatomical sites such as regions of
inflammation. For instance, anti-TNF Nbs that are coupled to anti-albumin do not only have improved
pharmacokinetic properties, but also accumulate in the inflamed joints of CIA mice [410]. Alternatively,
in an attempt for improved local delivery to the inflamed joint, TNF-inhibitors were coupled to
a single-chain variable fragment (scFv) that recognize collagen type II that is post-translationally
modified by reactive oxygen species (ROS) [411], and the so-called MYSTIs introduced in the previous
section, also aim for site-directed TNF neutralization. Others also investigated the possibility of
simultaneous targeting of MMP14 or cadherin-11 together with TNF in an attempt to direct the
pannus-cartilage junction in RA-affected joints [393].
7. Concluding Remarks
It is clear from the increasing amount of studies regarding the differential roles of the TNF
receptors, the TNF format, i.e., tmTNF or sTNF, and the function of TNF derived from specific cell
subsets, that the use of anti-TNF drugs can be improved or adjusted to the specific disease context.
Given the relatively long-time experience with the approved anti-TNF drugs, they can be considered
as relatively safe; however, improvements are warranted. In addition to the disease settings for which
a market authorization is settled, many other diseases in which a specific TNF subtype/receptor
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is involved can be approached. The examples are numerous and exceed the field of neurology
although this was mainly the focus in this review. Selective TNFR1 targeting is described for dry-skin
induced chronic itching [412], neuropathic pain [136], ventilator-induced acute lung injury [356],
eye disorders [203], and cardiomyopathy and myocardial ischemic injury [413–416], and this list is not
limited to these examples.
Although the expression of TNFR2 is limited in healthy conditions, in (autoimmune) diseases,
the expression of TNFR2 is significantly elevated. Importantly, TNFR2 has a superior toxicity profile
because of its limited tissue expression compared to the ubiquitous expression of TNFR1 [349].
As discussed in the manuscript, TNFR2 agonism is an attractive checkpoint therapy to modulate
the immune regulation through Treg activation, which can be very interesting in, for instance,
graft-versus-host disease [369]. Therapies that combine the two strategies in diseases, in which TNFR1
signaling leads to devastating outcomes and stimulation of TNFR2 is needed to promote proliferation
or regeneration, to achieve replenishment of the nonfunctional Treg population are attractive.
Additionally, as discussed, cell-specific drugs that are directed against the intended TNFR
expressed by a specific cell type are interesting for future research. This would lead to local
accumulation, less undesired side effects and thus safer therapies. Collectively, during the development
of new innovative therapies, one can not only consider the removal of the detrimental cells or signals
that are present, e.g., blockage of the inflammatory TNFR1 pathway or removal of autoreactive T cells,
but also think about therapies that stimulate the cells or cellular properties that are defective such as
suppressive cell types. Therefore, therapeutic treatments should always find the ideal balance between
doing enough good and preventing bad.
In addition, critical notes are needed, and considerable attention should be paid to adverse
effects that might pop-up with TNFR1 antagonizing treatments, as the sensitivity to several infectious
diseases is clearly increased in mice lacking TNFR1 [417]. However, cell-specific TNFR1 targeting
might again offer a solution to increase the safety. Besides, antagonizing a receptor always carries the
risk that the receptor is not blocked but instead becomes activated. This event has already previously
been described by others, and even led to early termination of a clinical trial [358]. Seemingly,
TNFR1 antagonists could not only be converted into potent receptor activators by the induction of
TNFR1-oligomerization, but agonistic activities can also be induced upon cross-linking by secondary
Abs such as by drug-induced antibodies or pre-existing antibodies that cluster the drug/receptor
complex and consequently activate the downstream pathway [358,418–420].
To conclude, therapeutic manipulation of TNF remains a very attractive field, and although we
know already a lot about the biology of TNF, there is a lot to uncover. This will allow us to select the
appropriate treatment for a specific patient population. In addition, improved patient empowerment
will drive the development of innovative medicines that deliver more relevant and impactful patient
outcomes [421]. Indeed, precision and personalized medicine are currently booming and the needs
of the patients should be considered when developing new drugs. Therefore, not only a profound
molecular understanding of the considered diseases is indispensable, but also the challenges faced
by the patients during their everyday living and their QoL should be accounted for during drug
development. Hence, a collaborative approach is essential and will facilitate the introduction of real
personalized medicine into clinical practice.
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Abbreviations
6-OHDA 6-hydroxydopamine
ADA Anti-drug antibody
ADAM A disintegrin and metalloproteinase
ADCC Antibody-dependent cellular cytotoxicity
ALS Amyotrophic lateral sclerosis
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
APC Antigen-presenting cells
AS Ankylosing spondylitis
Aβ(O) (oligomerized) Amyloid beta
BACE1 Beta-secretase 1
BBB Blood–brain barrier
BCG Bacillus Calmette-Guérin
CAIA Collagen antibody-induced arthritis
cAMP Cyclic AMP
CASP Colon ascendens stent peritonitis
CD Crohn’s disease
CDC Cell-dependent cytotoxicity
CIA Collagen-induced arthritis
CLP Cecal ligation and puncture
CNS Central nervous system
COX-2 Cyclooxygenase-2
CSF Cerebrospinal fluid
DC Dendritic cell
DD Death domain
DILE Drug-induced lupus erythematosus
DSS Dextran sodium sulfate
EAE Experimental autoimmune encephalomyelitis
EMA European Medicine Agency
FADD Fas-associated death domain
FcγR Fcγ-receptor
FDA Food and Drug Administration
FDC Follicular dendritic cell
GC Germinal center
GVHD Graft-versus-host disease
HT 5-hydroxytryptamine
hTNF Human TNF
ip Intraperitoneal
IBD Inflammatory bowel disease
icv Intracerebroventricular
IEC Intestinal epithelial cells
IFN Interferon
IFNAR Interferon-α receptor
Ig Immunoglobulin
IL Interleukin
JIA Juvenile idiopathic arthritis
KO Knockout
LPS Lipopolysaccharide
LTD Long-term depression
LTP Long-term potentiation
LT-α Lymphotoxin-α
mAb Monoclonal antibody
MDSC Myeloid-derived suppressor cells
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MMP Matrix metalloproteinase
MOF Multiple organ failure
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MS Multiple sclerosis
MTX Methotrexate
Nb Nanobody
NEC Necrotizing enterocolitis
NK Natural killer
NOD Non-obese diabetic
OLG Oligodendrocytes
OPC Oligodendrocyte precursor cell
PD Parkinson’s disease
PEG Polyethylene glycol
PLAD Pre-ligand assembly domain
PPMS Primary progressive MS
PsA Psoriatic arthritis
QoL Quality-of-life
RA Rheumatoid arthritis
ROS Reactive oxygen species
RRMS Relapsing-remitting MS
scFv Single-chain variable fragment
SIRS Systemic inflammatory response syndrome
SLE Systemic lupus erythematosus
sTNF(R) Soluble TNF(R)
TACE TNF-α converting enzyme
TDM Therapeutic drug monitoring
TIMP Tissue inhibitor of metalloproteinase
tmTNF Transmembrane TNF
TNF Tumor necrosis factor
TNFR Tumor necrosis factor receptor
TRADD TNFR1-associated death domain
TRAF(2) TNF receptor-associated factor (2)
TRAPS TNF receptor-associated periodic syndrome
Tregs Regulatory T cells
UC Ulcerative colitis
VHH Variable domain of heavy-chain only Abs
VNAR Variable new antigen receptor
WT Wild type
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